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INDUCTION OF THYMIC LYMPHOMAS
IN RFM AND C57BL MICE BY N-
METHYL-N-NITROSOUREA. P. M. Fity
P. D. LAWNLEY and J. V. FREI, Institute of
Cancer Research, I'ollards Wood Research Station,
Chalfont St. Giles, Bucks.
We have examined 2 strains of mnice (RFMI
and C57BL) with very different stusceptibilities
to the induction of thymic lymphomas by
X-rays, to see whether a similar difference
occturs wheni this tumnouir is induiced by N-
methyl-N-nitrosourea (AINUA). W=e fouind that
relatively low doses of AINUA produced a high
yield ofthymnic lymphomas in female RFrn1 mice,
but mtuch higher doses were needed to prodtuce
the same tuimour yield in males or in C57BL
mice. Marrowr depletion after a single dose of
40 mg/kg MINUA was also showvn to be greatest
in female IRFMI mice, but the extent of thymus
damage was very simnilar to that in males or
C57BL mice. V'ery low, non-tumorigeniic doses
of MNUA were also shown to produice significat-t
thymus damage in both strains, but the effect
on the marrow cell count was negligible. This
confirms previous suggestions that marrow
depletion is the more significant event in the
initial stages of tuimotur development (Frei &
Maitra, 1974, Chem.-Biol. Interact., 9, 65). The
carcinogenic effect of MNUA is also thought to
be related to its ability to induce 06-methylation
of DNA guianine (Loveless, 1969, Nature, 223,
206). Preliminary resuilts suggest that the extent
of this type of methylation is greater in female
RFAI inice than in males or C57BL inice, provid-
ing fuirther positive stupport for the correlation
betw-een this chemical event and the induction
of thymnic lymnphomas.
COMPARISON OF THE EFFECTS OF
NEOSOLANIOL, A TRICHOTHECENE
METABOLITE OF FUSARIUM SPECIES,
WITH THOSE OBSERVED IN RODENTS
GIVEN T-2 TOXIN. R. SCHOENTAL, A. Z.
JOFFE and B. YAGEN, The Royal Veterinary
College, London, and The Hebrew University,
.Jerusalern,.
Neosolaniol (30s, 8o-dihydroxy-4fl, 15-diacet-
oxy-12, 13-epoxy-trichothec-9-en), which differs
from T-2 toxin- by the absence of the isovaleryl-
residue at C-8, is often present in cultures of
Fusariutn? spp., which produce T-2 toxin (Ueno,
p. 189; Yagen et al., 1977, p. 329 in Mycotoxins
in Human and Animal Health, Pathotex Publ.).
Neosolaniol has been fouind in the exereta, as
one of the mnetabolites of T-2 toxin, in broiler
chicks; the chick excreta appears to concentrate
T-2 toxins and its mletabolites to a great extent
(Mirocha et al., 1978, Int. Conf., Mlycotoxins,
Abstr. p. 28). Thouigh neosolaniol is kiiown to be
less actutely toxic than T-2 toxin (its LD50 is
moie than- douible that of T-2 toxin), the extent
to which it contributes to the carcinogenic and
other pathological effects seen- in rodents given
T-2 toxin (Schoental et al., 1978; Experinmentia,
34, 763; Br. J. Canctcer, 38, 171) has not been
knowsn. Some of the lesions fouind in rodents
treated with neosolaniol -will be described. The
uise of chickeni excreta as suipplement to poultry
diet can occasionally present a health hazard to
the birds, and possibly to their consumers.
ENVIRONMENTAL FACTORS IN LYM-
PHORETICULAR CANCER. C. R. GILLIS,
D. .J. HOLE and P. BOYLE, Cancer Intelligence
Unit, Ruchill Hospital, Glasgou.
In 'Vestern Scotland and in other parts of the
world, the incideince ofleukaemia and lymphoma
is in-creasing. AMost of this increased frequency
is accounted for by individuals above the age
of60, and is more apparenit inmales than females.
Socio-econoinic and ethnic variables contradict
evidenice from mortality studies. The effects of
high levels of strontium-90 in the atmosphere
has been stuidied in relation to childhood leui-
kaemia and lymphoma by means of cohort
analysis for birth cohorts assembled before,
during and after the period when 90Sr levels
were raised by uip to 5 times that previously
considered "normal". The phenomenon of
space-time cluistering has been examnined exten-
sively, in an optimal situation in terms of
geography, and also in an optimal situationi in
terms of aetiology. Neither studies appear usefuil
in determining the place of this techniquie in
assessing the value of aetiological hypotheses.
A study of 6000 chemical Mworkers involved
in the manuLfacture of explosives for com-
inercial uise has been carried out and an
increase of both letukaemnia and lymphoma
demnonstrated, althouigh there does not yet
appear to be a common factor in the occupa-
tional exposuire ofthe chemical workers involved.
Fiially, prospective stuidy of 120 cases of
Sj6gren's syndroine may indicate new ap-
proaches to the epidemiological stuidy of the
lymphoreticular cancers.
ALCOHOL CONSUMPTION, CIGAR-
ETTE SMOKING, CANCER AND RE-
LATED DISEASES IN WESTERN SCOT-
LAND. C. H. GILLIS, D. J. HOLE and P. BOYLE,
Cancer Intelligence Unit, Ruchill Hospital,
Glasgow.
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The West of Scotland has traditionally been
associated with a high incidence of lung cancer
and a high frequency of alcoholism. A retro-
spective case-control study has been carried out
on a single-blind basis amongst , 2000 hospital
patients broadly representative of the general
population of WVestern Scotland. This paper
explores the relative and attributable risks for
various cancers in relation to detailed history
of cigarette smoking habits and alcohol con-
sumption analysed for both these factors separ-
ately and in combination. Each "case" has been
compared with 2 age- and sex-matched controls.
Validity checks ofthe data have been instituted.
The results are presented in relation to lung,
colon, bladder and other cancers for which
epidemiological associations have been estab-
lished with either cigarette smoking, alcohol
consumption or both. The results form part of
an international collaborative study being
carried out in France, Austria, Italy, Germany,
The United States of America and Cuba, and
the West of Scotland shows interesting differ-
ences. Whilst some of these may simply be
related to differences in incidence, the size of the
observed differences between Scotland and the
other countries strongly argues the implication
of some other major factor amidst the groups
being studied. At present, differences in nutri-
tional status appear to be the most fruitful
avenue for further exploration.
GROWTH STIMULATION OF CAPIL-
LARY ENDOTHELIAL CELLS BY
TUMOUR ANGIOGENESIS FACTOR
(TAF). A. M. SCHOR, S. L. SCHOR and S.
KUMAR, Christie Hospital and Holt Radiun
Institute, Manchester.
Semipurified tumour extracts able to induce
neovascularization in vivo (TAF) (Folkman
et al., 1971, J. Exp. Med., 113, 275) have been
reported either to have no mitogenic effect or to
inhibit endothelial cell growth in vitro (Phillips
et al., 1976, Int. J. Cancer, 17, 549). We found
that TAF had a mitogenic effect on endothelial
cells derived from cow brain only when the
cells were growing on collagen (native fibres,
Type I) and in the presence ofplatelets or plate-
let-released factors (PRF). No stimulation of
cell growth occurred when the cells were
growing either on plastic tissue-culture dishes
(with or without platelets or PRF) or on collagen
in the absence of platelets or PRF.
The different response of the cells according
to the substratum on which they grow is not
due to a selection of a cell subpopulation on
collagen or to an interaction between TAF and
collagen. It seems therefore to result from a basic
difference in cell physiology induced by the
substratum.
EFFECT OF C. PARVUM ON BLOOD
COAGULABILITY IN MICE. H. D. MITCHE-
SON, P. HILGARD and J. E. CASTRO, Depart-
ments of Urology, Transplantation and Haerna-
tology, Royal Postgraduate Medical School,
Hammersmith Hospital, London 1V12.
Iv. injection of 350 jig of C. parvurn produces
severe haematological changes in C57BL mice,
maximal at 7-12 days. The main features are
pronounced thrombocytopenia and anaemia.
Concomitantly a decrease in plasma fibrinogen
and an increase in serum fibrin degradation
products is fotund. No significant changes in the
prothrombin time and partial thromboplastin
time are seen. All animals survive and haemato-
logical variables recover to normal by Day 21.
Similar findings are recorded when C. parvuwt
is injected i.p., although the time course is
different.
To elucidate further the mechanisin of the
thrombocytopenia, a platelet-turnover study
was conducted in animals injected with C.
parvum 7 days earlier. Compared to the corres-
ponding control animals, there was asignificantly
shortened platelet half-life. Although the overall
radioactivity in the enlarged spleen and liver
was higher than in the controls, relative radio-
activity on a ct/min/mg tissue basis w\as de-
creased. Light microscopy revealed a few
thrombi in the lungs, as well as massiv-e infarcts
and thromnboses in the liver of C. parvum-
treated animals. The present data, however, are
not fully compatible with the assuinption that
disseminated intravascular clotting is the only
cause for the haematological changes after C.
parvum injectioin.
DOES THROMBOCYTOPENIA AFTER
C. PARVUM AFFECT METASTASIS?
P. D. E. JONES, H. D. MITCHESON and J. E.
CASTRO, Departrnent of Urology, Royal Post-
graduate Medical School, Hamninersmith Hospital,
London W12.
Are have previously show-n that i.v. inijection
of 466 jug of formalin-killed C. parvum (straill
CN6134) inhibits the growth arid pulmnonaiy
metastasis of an s.c. implant of the Lewis lung
carcinoma in C57BL mice, and also causes
prolonged thromnbocytopaenia. Another strain
(CN5888) which had n-o antittmnour effect,
caused only transient thrombocytopenia. WVe
therefore suggested that the thromnbocytopenia
might contribute to the antimetastatic effect
(Jones et al., 1977).
To test this hypothesis wve have nowN sttudied
the effects of different doses of C. parvunm (CN
6134) on tumour development and also deter-
mined the numbers of peripheral platelets inI
these mice. A 70[kg dose given i.v. on the same
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day as tumour was as effective as a 466,ig dose
at inhibiting tumour growth and metastasis,
but induced a less marked thrombocytopenia.
A dose of 35 Hg caused thrombocytopenia to
the same extent as 70 ,ug, yet was without anti-
tumour effect. Furthermore, when Lewis tumour
cells were injected into mice thrombocytopenic
due to C. parvum, there was no correlation
between the degree of thrombocytopenia and
number of pulmonary metastases. Indeed, sig-
nificant enhancement ofmetastasis occurred at a
time when the platelet count was low.
We therefore feel that the antimetastatic
effect of C. parvum is unrelated to its effects on
peripheral platelets.
TUMOUR-CELL SENSITIVITY SCREEN-
ING IN VITRO IN A ROUTINE PATH-
OLOGY LABORATORY. R. W. BILLINGTON
and P. SECRET, Pathology Department, Highland
Area Laboratories, Raigmore Hospital, Inverness.
An attempt has been made to set up an in
vitro screening service for tumour-cell drug
sensitivity. Specimens are received from hos-
pitals in the Highland Health Board and West-
ern Isles Health Board Areas. The first object
of the study was to determine the feasibility of
growing tumour cells direct from surgically
removed tumour specimens in such a way that a
reasonably pure tumour-cell population could
be obtained in sufficient quantity to permit
testing with various anti-cancer drugs.
The second objective was to establish an in
vitro screening method using the limited facilities
available in a routine pathology laboratory.
Specimens were obtained direct from the
operating theatre. Adjoining pieces of macro-
scopically suspicious areas were taken for growth
and routine histology. All tumours received were
processed for growth, regardless of histological
type. A combination of mechanical and enzymic
disaggregation was used, and it was found that
the use of collagenase gave the best chance of
growth establishment. When a cell population of
sufficient size and purity was established, cells
were tested against appropriate concentrations
ofcytotoxic drugs in microtest plates. Cell death
as compared with controls was estimated by
simple cell counting. 245 tumour specimens were
received, and in 211 (86%) successful in vitro
growth was established. Epithelial-type cells
predominated in 134 (550o) and in 63 (26%)
growth characteristics were such that a drug
sensitivity test could be carried out. Detailed
results on individual tumour types will be
presented. It is concluded that the test has a
limited but possibly important role in tumour
control in individual patients.
METHIONINE DEPENDENCE OF
TUMOUR CELLS. M. J. TISDALE, Depart-
ment of Biochemistry, St Thomas's Hospital
Medical School, London SE1 .
Unlike normal cells in tissue culture, which
grow equallywell eitherin mediumsupplemented
with methionine, or in methionine-depleted
media containinghomocysteine, vitamin B12 and
folic acid, certain tumour and transformed cells
show stringent methionine requirements. The
inability of such cells to grow in methionine-
deficient media is not due to a loss of 5-methyl-
tetrahydrofolate: L-homocystein S-methyltrans-
ferase, since the activity of this enzyme in
Walker carcinoma, which shows an absolute
methionine requirement, is similar to that found
in TLX5 lymphoma, which is able to proliferate
equally well in media containing homocysteine,
but no methionine. Furthermore, when Walker
cells are cultured in such deficient media there is
a 10-fold induction of enzyme activity over a
48h period, and the level of activity is propor-
tional to the methionine content of the medium.
The methionine auxotrophy is also not due to a
lack of reduced folate, a source of methyl
groups, or to inadequate levels of polyamines or
methylthio groups for growth. Under conditions
of methionine deprivation the level of S-
adenosylmethionine in Walker carcinoma is
severely reduced whilst the level in TLX5
lymphoma is little affected. The inability of
some malignant cells to grow at low methionine
concentrations may be due to their greater
methionine requirements due for example to
increased tRNA methylation.
IN VITRO PREDICTIVE TESTING OF
ASTROCYTOMA. D. MORGAN and R. I.
FRESHNEY, Beatson Institute for Cancer Re-
search, Glasgow.
A scintillation autofluorographic technique
(Freshney & Morgan, 1978, Cell Biol. Int. Rep.,
2, 375) has been used to assay the in vitro
sensitivity of astrocytoma cells derived by
collagenase digestion of biopsy samples (Fresh-
ney, 1972, Lancet, ii, 488) to a range ofcytostatic
agents with a view to predicting which drugs to
use clinically.
Cells are exposed to the drugs for 2 population
doublings and allowed to recover for 2 doublings.
The 50% inhibitory dose (ID50) is measured at
various points in the assay. The intrinsic varia-
tion of the assay is very low, but significant
variations in response are measured between
different cell lines. Vincristine shows the widest
range of sensitivities, the most sensitive retain-
ing their sensitivity throughout the assay. Some
cell lines recover rapidly from procarbazine
although others show delayed response. Most cell
lines recover rapidly from methyl-CCNU. This,
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information could be important clinically when
determining a patient's chemotherapy pro-
gramme.
The response of biopsy samples from human
astrocytoma being grown as xenografts in
immune-deprived mice is being compared with
the response in vitro.
THE STRUCTURAL ORGANIZATION OF
MULTIPLE-GENERATION C3H MAM-
MARY TUMOUR AND ITS IMPLICA-
TIONS FOR RADIATION TREATMENT.
A. S. ABDELAAL* and A. H. W. NIASt, *Radio-
biology Research Group, Glasgow Institute of
Radiotherapeutics and Oncology, Belvidere Hos-
pital, Glasgow, tNow at St. Thomas's Hospital
Medical School, London SE1 7EH.
In mouse skin, the blood capillaries are dis-
tributed superficially and deep to the panniculus
carnosus muscle (PS). The deeperpartofthesub-
cutaneous layeris loose and avascular connective
tissue. This structural arrangement and its
disorganization by the growing tumour mass,
determine the processes of perfusion and diffu-
sion at different regions ofthe tumour; hence its
structural organization (signet-ring appearance).
When a cell suspension is used for s.c. trans-
plantation, the tumour cells in the vicinity of
PS muscle encircle the numerous blood capil-
laries in that region, whilst those at a deeper
level depend more on diffusion for 02 and
nutrition and form a -100 ,tm rim of viable
tumour cells outlining an eccentric necrotic area.
The latter type of growth appears to occur in
the absence of nearby stromal blood vessels.
After irradiation, massive necrosis occurs
towards the central part of the tumour, leaving
only a thin rim of tumour cells, in a state of
incomplete cell division. This is observed after
X-rays alone and X-rays in combination with
misonidazole. Tumour cells forming this rim
seem to differ from the rest in a way which main-
tains cell division for a limited period in the
majority of cells but indefinitely in one or more
cells. The latter would be responsible for tumour
recurrences.
GAPS IN TREATMENT: RADIOBIO-
LOGICAL ASPECTS OF A CLINICAL
PROBLEM. R. HAMLET*, A. M. PERRYt and
J. KIRK*, *Radiobiology Research Group. Glas-
gow Institute of Radiotherapeutics and Oncology,
Belvidere Hospital, and tWest of Scotland Health
Boards, Department of Clinical Physics and Bio-
Engineering, Glasgow.
The Cumulative Radiation Effect (CRE) is
one of several empirical mathematical scalar
descriptions of biological effect which enable
corrections to be made for gaps in radiotherapy
treatment. Predictions of this formulation were
tested using mouse intestine and mouse skin as
biological models. The results ofthe experiments
demonstrated that if a gap occurs early in a
treatment schedule, a much larger additional
dose is needed to compensate for the amount of
repair which occurs, than is predicted by the
formula. Also if a gap occurs towards the end
of a schedule a much lower additional dose is
required than is predicted. Thus the simple
model of exponential repair during a gap wher-
ever it occurs in treatment, which is proposed
in the present CRE model, has been shown to be
inadequate, and future models must take into
account the fact that the regeneration potential
of a tissue will vary in a more complex way
depending on the level of damage achieved
before the gap in treatment occurs.
STUDIES WITH THE HYPOXIC CELL
SENSITIZER RO 05-9963 IN THE DOG.
R. A. S. WHITE, P. WORKMAN, L. N. OWEN and
N. M. BLEEHEN, M.R.C. Clinical Oncology and
Radiotherapeutics Unit, Hills Road, and Dept.
Clinical Veterinary Medicine, Madingley Road,
Cambridge.
Hypoxic cell sensitizers, in particular misoni-
dazole (Ro 07-0582) are currently of interest in
radiotherapy,butappeartohavelimitingtoxicity
associated with persistence ofthe drug. We have
therefore investigated the pharmacokinetics and
tumour penetration of another 2-nitroimidazole,
Ro 05-9963, produced as a metabolite ofmisoni-
dazole (MIS) and reported to be equally as
effective as a radiosensitizer in mice (Adams
et al., 1976; Flockhart et al., 1978). I.v. adminis-
tration produced rapid peak plasma concentra-
tions which were 60% higher than those for a
corresponding dose of MIS. Ro 05-9963 was
found to have a short biological half-life in this
species, 2-4 h for i.v. dosage and 1-8 h for oral,
as compared with MIS (4.7 h for both i.v. and
oral dosage). The resulting area under the curve
(AUC) for i.v. dosage was only 50% of that
recorded for MIS; that for oral administration
was still less because of poor bioavailability
(66%). Concentrations in CSF were slow to
increase and low peak concentrations were
recorded. Investigation ofRo 05-9963 concentra-
tions in repeated biopsy samples of several
spontaneous canine tumours revealed a tumour:
plasma ratio of 60-70%, similar to that recorded
for MIS; initial concentrations were markedly
higher than those for MIS. We conclude that,
when administered i.v., Ro 05-9963 achieves
greater tumour concentrations than a similar
dose of MIS, whilst the reduced AUC has impli-
cations for possible reduced toxicity.
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CYTOTOXICITY OF MISONIDAZOLE
IN VIVO UNDER CONDITIONS OF PRO-
LONGED CONTACT OF DRUG WITH
THE TUMOUR CELLS. J. M. BROWN*t and
N. Y. Yu*, *Dept. of Radiology, Stanford Univer-
sity School of Medicine, California, U.S.A., and
tMRC Clinical Oncology and Radiotherapeutics
Unit, Cambridge.
It has been suggested that, although direct
cytotoxicity can be observed in mouse tumours
after injections of high doses of misonidazole
(MIS), the fact that the half-life of AIIS in the
mouse (1-2 h) is shorter than in man (- 12 h)
means that the cytotoxic effect of electron-
affinic sensitizers is likely to be more important
clinically than is apparent from the mouse model.
Stratford & Adams (1978, Br. J. Radiol., 51,
745) have shown, in fact, that such an effect can
be demonstrated in vitro: they found greater
cytotoxicity of hypoxic V79 cells with an initial
concentration of 0-5mM MIS and a dilution
half-life of 12 h, than w th an initial concentra-
tion of 5 mm and a dilution half-life of 1 h.
We have partially simulated this experiment
in vivo by prolonging the half-life of MIS plus
its 0-demethylated metabolite Ro 05-9963 from
roughly 1 h to 7 h by bilateral kidney ligation.
However, despite the fact that cytotoxicity
could be demonstrated in the EMT6/St/lu
tumour after a high dose of MIS (5 mmol/kg);
there was no evidence for cell killing of hypoxic
cells in the tumours in kidney-ligated mice
after a low drug dose (0.5 mmol/kg). It is
possible, therefore, that the cytotoxic effect (as
distinct from the radiosensitizing effect) of MIS
may not contribute significantly to its clinical
usefulness.
THE EFFECT OF TIME BETWEEN X-
IRRADIATION AND CHEMOTHERAPY
(ADM, CTX, CIS-DDP, ACT-D, BLM,
OR BCNU) ON THE GROWTH OF 3
SOLID MURINE TUMOURS. P. R. TWEN-
TYMAN*, R. F. KALLMAN & J. M. BROWN.
Stanford University School of Medicine, Stan-
ford, California, U.S.A.
The effect of interval between X-irradiation
(1200 rad) and drug administration was deter-
mined for growth delay in 3 solid tumours in the
mouse. The tumours used were EMT6 in BALB/c
mice, and the KHT and RIF-1 sarcomas in
C3H mice. All tumours were grown intra-
muscularly in the hind limb, and treatments
were carried out at a mean tumour weight of
450 mg. Time to reach 2 x (for KHT) or 4 x (for
EMT6 and RIF-1) treatment volume was used
as the endpoint. Adriamycin (6 mg/kg), cyclo-
phosphamide (100 mg/kg), cis- diamminedi-
* Present address, MRC Clinical Oncology and
Radiotherapeutics Unit, Hills Road, Cambridge.
chloroplatinum (7 mg/kg), actinomycin-D (0-2
mg/kg), bleomycin (20 mg/kg), or BCNU (15
mg/kg) was administered i.p. at either 24, 6,
or 2 h before irradiation, immediately before
the start of irradiation, or at 3, 6, or 24 h after
irradiation. All the irradiations were carried out
in unanaesthetized mice. The drug doses were
chosen either to produce a growth delay of a
few days for drug alone, or (for those drugs
giving no significant growth delay) to approach
the maximum tolerated dose. For none of the
drugs was there any consistent time dependence
on the interval between drug and radiation
administration of the growth delay produced in
the 3 different tumour systems. In most of the
experiments the growth delay produced by drug/
radiation combinations was not significantly
different from the addition of the growth delays
produced by the single modalities.
IS THERE A DIFFERENCE IN THE
RANGE OF RADIOSENSITIVITY BE-
TWEEN NORMAL INDIVIDUALS AND
HETEROZYGOTES FOR ATAXIA
TELANGIECTASIA (AT)? A. M. R. TAYLOR
and C. M. ROSNEY. Department of Cancer
Studies, The Medical School, Birmingham, B15
2TJ.
It has been suggested that individuals hetero-
zygous for the AT gene show significantly
increased numbers of deaths from carcinoma,
lymphoma and leukaemia, and that in hetero-
zygoes under 45 years the risk of dying from
cancer was more than 5 x the risk in the general
population (Swift et al., 1976, Cancer Res., 36,
209). If this is the case it would be very useful
to be able to detect such individuals. In the
heterozygous state, however, the gene does not
manifest any clinical features. The homozygotes
have been shown to be unusually radiosensitive,
so we have tested the possibility that hetero-
zygotes show a radiosensitivity intermediate
between the range of normals and AT homo-
zygotes. Using cell-survival methods, our results
suggest that there is no difference in radio-
sensitivity between our AT heterozygotes and
our range of normals.
METASTASIS FOLLOWING HYPER-
THERMIA OR X-RAYS. A. WALKER*, A. S.
ABDELAAL*, H.M.MCCALLUMt, T. E. WHELDON*
and A. H. W. NIAS*j, *Radiobiology Research
Group, Glasgow Institute of Radiotherapeutics
and Oncology, Belvidere Hospital, Glasgow,
tRoyal Beatson Memorial Hospital, Glasgow G3.
We have examined the response of the C3H
mouse mammarycarcinoma, dorsallyimplanted,
t Now at St Thomas's Hospital Medical School.
London SEI.
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to X-rays and to local hyperthermia. We found
locally curative X-ray dosages to lie in the region
5000-8000 rad and locally curative hyperther-
mia to lie in the temperature region 42-450C
and the time range 1-2 h. Hyperthermia was
administered to unanaesthetized animals by
water pumped through a heating device, using
a fine membrane as interface, the temperature
being constantly monitored.
During the course ofthe hyperthermia studies,
we noted a high incidence of unexpected deaths
in locally cured mice, and this observation
prompted the instigation of necropsy, not
hitherto routine. All mice examined by necropsy
because of early death or visible deterioration
in absence oflocal tumour proved to have distant
metastases, usually in the lungs, but occasionally
in kidney, brown fat or other sites. The incidence
of proven metastases (14/52 or 27%) in hyper-
thermia-cured mice may be contrasted with the
maximum incidence of metastases (14/131 or
11%) inferred from early death of mice locally
cured by X-rays. By the X2-test this difference
is significant (P < 0.02). A controlled prospective
trial has now confirmed a significant (P <0-01)
increase in frequency of metastases after hyper-
thermia (14/77 or 18%) as compared to X-rays
(0/32).
Pending confirmation of this phenomenon,
and of investigation of the causal mechanisms
and exploration of possible ways of obviating it
(e.g. by pre-irradiation) clinical trials involving
treatment with local hyperthermia alone of
human tumours of known metastatic potential
should proceed with caution.
EFFECTS OF THE COMBINATION OF
HYPERTHERMIA AND CYTOTOXIC
DRUGS ON THE SKIN OF THE MOUSE
FOOT. D. J. HONESS and N. M. BLEEHEN,
MlRC Clinical Oncology and Radiotherapeutics
Unit, Cambridge.
Hyperthermia has been demonstrated to
increase the cytotoxic effect of some drugs on
tumours. This study reports the results of such
combined treatments on the normal mouse foot,
with a view to determining whether there may
be a therapeutic advantage in such treatments.
Heating is by means of hot water, under pento-
barbital anaesthesia. Dose-response curves for
heat alone at 43°C, 43.5°C and 44°C have been
obtained. The 3 drugs so far studied at 40°C
for 60 min are adriamycin, BCNU and cyclo-
phosphamide. Adriamycin at 10 mg/kg and
6-7 mg/kg does not enhance the skin damage.
BCNU at 20 mg/kg and cyclophosphamide at
200 and 133-3 mg/kg do cause marked enhance-
ments. Because these drugs are immuno-
suppressive, it is possible that the enhancement
may be due to an impairment of healing or of
combating infection. The possibility that im-
paired healing was due to a systemic effect ofthe
drug was investigated by pretreating the mice
24 h before heating with either 500 rad whole-
body irradiation or cyclophosphamide or BCNU.
No enhancement of the response to heat was
seen. However, cyclophosphamide given 6 h
after heating does give an enhanced reaction.
COMBINATION HYPERTHERMIA (42°C)
AND HYPERGLYCAEMIA IN THE
TREATMENT OF THE MC7 SARCOMA.
D. J. JACKSON and J. A. DICKSON, Cancer
Research Unit, University Dept. of Clinical
Biochemistry, Royal Victoria Inftrmary, New-
castle upon Tyne.
Potentiation of the destructive effects of
hyperthermia on tumours by low pH was re-
ported by Von Ardenne (1972, Adv. Pharmacol.
10, 339). It was claimed that prolonged (3-5 h)
hyperglycaemia in vivo selectively stimulated
tumour glycolysis and increased lactic acid pro-
duction, thereby inducing a state of "optimized
tumour hyperacidity". Activation of lysosomal
enzymes ensued and potentiated hyperthermic
damage.
After hyperthermia (42°C/3 h) the syngeneic
MC7 sarcoma on the foot of rats regressed com-
pletely (mean volume-halving time 4 days) with
cure of the host. Hyperglyeaemia (blood glucose
> 400 mg% for 7 h) led to a 7-10-fold increase
in tumour lactate concentration and extra-
cellular pH (pHe), measured by capillary glass
electrode, fell from 7-15 to 5-99. Tumour intra-
cellular pH (pHi), measured by a triple-isotope
technique (1978, Cell Biol. Int. Rep., 2, 327),
decreased from 7-22 to 6-30 and there was a
10-day restraint oftumour growth. When hyper-
thermia was applied during the last 3 h ofhyper-
glycaemia, the tumours regressed with a mean
volume-halving time of 2-9 days significantly
(P < 0.02) shorter than after hyperthermia alone.
With the Yoshida sarcoma, pHe fell from
7-19 to 6-63, while pHi increased from 7-21 to
7-36 after hyperglyeaemia, and tumour growth
was not further inhibited by adding hyper-
glyeaemia to heat.
Additional data on the pHe/pHi relationship
for these tumours supports the conclusion that
the glucose sensitizing effect for heat depends on
inadequate pHi buffering in the face of a low
pHe.
EFFECT OF HYPERTHERMIA (42°C) ON
BLOOD FLOW IN THE YOSHIDA SAR-
COMA AND NORMAL TISSUES. S. K.
CALDERWOOD and J. A. DICKSON, Cancer Re-
search Unit, University Dept. of Clinical Bio-
chemistry, Royal Victoria Infirmary, Newcastle
upon Tyne.
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The Yoshida sarcoma on the foot of rats
(1 0-1 5 rnl) can be cured by 1 h at 42 C (intra-
tuimour temnperatuire). The selective heat sensi-
tivity of tumnouirs has been attribtuted to a
sluggish blood flow with ani inadequiate ability
to dissipate heat load compared to normnal
tissues (J. Am. 31l, d. Ass., 1976, 235, 2198).
Blood flow w%-as measured isotopically by
uiptake of 86Rb (1958 An^. J. Physiol., 161, 193).
Rate of blood flow in the 1 0-1 5 ml Yoshida
foot sarcoma was higher than in resting muscle
and normal skiii (0-41 coinpared to 0-19 and 0-1:3
mnl/g dry wt/min respectively) but was only
1/30tlh that of the kidney (12-51 inl/g/min).
After 1 h at 42°C, blood flow in normal rat
skin increased froin 0 13 to 2-33 inl/g/mnin and
then decreased to 0 8-1 2 inl/g/min as heating
contintued to 2 an-d 3 h. In the tulmotui, 1 h at
42°C cauised no alteration in blood flow, but
continuation of the heating decreased blood
flow to 0 15 inl/g/inin at 2 h and to zero at 3 h.
The tuim:oulr diffeIed fIroin nloIr-mal skini in its
response to heat in 2 ways: (a) no increase in
ttumouir blood flowr occturied at raised temnpera-
ture (b) heating of the ttumoui foI longer than
l h inhibited tuimouir blood flow. If applicable to
ttumnouirs in general, these findings, with the
concomitant imicrease in blood flow throtugh nor-
mnal tissuies (e.g. skin) have impoitant imiplica-
tions for heat therapy of cancer, since they
enable the tumour-heating temi-peratture to be
meduiced with tirne as wNell as protecting the
norinal tissuies fromn heat damage.
THE VALUE OF ROUTINE TESTS OF
IMMUNOLOGICAL FUNCTION. D. J.
HOLE, C. H. (GILLIS, 13. R. STACK anid E. KIRK-
WN'OOD, Cancer Intelligence t nit, Ruchill Hospital,
Glasgoi%.
The potential x-alue of uisinig routine tests of
immuorllogical fuinction sequentially as a means
of assessinig a patient's clinical conditioni has
beei-n assessed as part of a clinical trial exaininglig
the effect of imnmunotherapy in operable bron-
chial carcinoma. 70 patients were tested pre-
operatively at wNeekly intervals for 3 weeks,
postoperatively 1 rnonth after discharge and
thereafter at 3-monthly intervals extending to
2 years; a total of 541 speciinens. BCG and
DNCB reactivity, lymphocyte couints and T-
and B-cell determinatioins Were inade in addition
to lymphocyte r-espouises to PHA, pokewNeed anid
PPD stimutlationi in each specimien. Apait fromn
changes in BCG reactivity, -vhich does i-elate
to the patient's clinical progress. and a decline
in T lymphocytes at abotut 9 inoniths, there
appears little consistency in the remainder of
the tests. The fall in T lymphocytes does not
occur early emiough to act as anl indicatoi for
those ab)out to exhibit recurrent disease. The
rfeinainder (if the laborai,tory tests show somne
variations which inay hav-e relevance to the
patients' progress, althouigh this is not clear. It
is considered that these r'estults imay be of sig-
nificance for the ftuttire of iimnni-llological testing
otn a routine basis.
LYMPHOBLASTOID CELLS AS INDICA-
TORS OF LYMPHOKINE GENERATION.
E. CUTLBERT anld A. J.. COCHRAN, 1t1 uiersity
Department of I'athology, IWestern? Infirm1ary,
Glasgow.
W e investigated the inigmcationi fri:omii capillary
tubes of cells fIoIn humnan- lyrnphoblastoil linles
and normnal huiman and inouse leucocvtes. Tl'his
is a metabolicallv actix-e pIrocess, inhibited by
lox- temperatuires (4 C) and inhibitors of glyco-
lysis, oxidative phosphorylatioin anid RNA/
proteinl synlthesis. MIigration is inhibited by
mediuim conditioned by actively grow(ving cull-
thres, possibly a result of depletioni of inuitrienlts.
The mnigratioii of niormnal humrnani and inouise
leuicocv,tes and cells fromn the linse Q1M1i{-Wll,
wsas afected (enthanced or inhibited) by super-
natants fromn cuiltuires in wvhich it was likely that
lymphokines had been genierated: PHA-stiinula-
ted lymphocytes and mixed-lyinphocyte reac-
tions (AILR). Th-e migratiorn of cells from the
line NAMIALWA -vas iiot affected by such simper-
natants, stuggestinig that these cells (0l not
respond to migration-inhibitory lyrinplhokines.
Inhibitorv activity in the stuperntatanits of ctul-
ttures of mouse spleen cells ptulsed x -ith PHA
(1 ag/mnl) increased with puilse duiration- aiid timne
of inctubation after pulsinig. MILR cutltuires also
produiced inhibitory actixvitv wshich iincreased
with time of incubationt. Stitablly conitrolled
experiments indicated that the inhibitory acti-
Vity wvas niot duie to at inediuiml-conditiolinlg'
offect.
Indicator lymnphoblastoid cells are being
assessed in a study of senisitizationi to ttuimlotur-
associated antigens by co-cultuire of hutma
lymphocytes ami(1 tuimourl or1 conltr'ol cells.
A RAPID METHOD OF SEPARATING
LARGE AND SMALL THYMOCYTES FOR
STUDY OF THEIR SURFACE PROPER-
TIES. J. (G. SALISBURY, .J. M\. GRAHAM and
C. A. PASTERNAK, Biochem istry 1)epartnent1, St
George's Hospital Medical School. Tooting, Lon -
dlon 51VW17.
Thvmocy\tes canl be (lixided ( into 2 broad
categories. The larger cells (diameter > 7 [tin)
constituite 10 200o of the total ai(Il have beemi
sho\nrl to be activelv dixiding. These cells give
i-ise to small thymocytes (<7 [tin diameter)
which constitute the majority of cells amid are
non-(fividing (Aletcalf & WXadrionvski, 1966,
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Cancer Res., 26, 483; Shortman & Jackson, 1974,
Cell. Immunol., 12, 230). The aim of this study
has been to separate these 2 populations and
study their surface properties.
A simple method has been developed to
separate the large and small cells from both
rats and mice, involving the use of a new
gradient material, Percoll (Pharmacia), which
is a silica colloid. The cells are mixed with
Percoll, the density of which is adjusted to lie
between that of the large (1-07 g/ml) and small
(1-086 g/ml) cells. At 1250 g the cells separate
to give a band of large cells at the top and a
pellet of small cells. A second spin ensures that
the large-cell fraction is >85%o pure. The
separated populations ofcells make a convenient
system for the study of the surface properties of
cycling and non-cycling cells.
Surface proteins of the 2 cell types are being
studied using the lactoperoxidase-catalysed
iodination (1125) method (Hynes & Humphreys,
1974, J. Cell Biol., 62, 438). The proteins are
extracted in SDS and separated by polyacryla-
inide gel electrophoresis.
COMPARISON OF THE IMMUNOGENI-
CITY OF CHEMICALLY INDUCED RAT
AND MOUSE TUMOURS. AI. R. PRICE,
R. G. DENNICK and L. W. LAW, Cancer Research
Campaign Labs., University of Nottinghamt, and
Laboratory of Cell Biology, NCJ, Bethesda, MD,
U.S.A.
Chemically induced rat hepatomas and sar-
comas express individually distinct turmour-
rejection antigens although immunization with
acellular preparations of tumour antigens are
ineffective in inducingprotection againsttumour-
cell challenge. Immunization with radiation-
attenuated hepatoma cells is optimally efficient
when the cells retain a residual metabolic acti-
vity. Conversely, with the 3-methylcholanthrene-
induced BALB/c murine sarcoma Meth A,
resistance to challenge with 2 x 104 viable
tumour cells is afforded by treatment with a
single injection of 105 X-irradiated cells and jg
quantities of partially purified tumouir antigen
are immunoprotective (see, for example, Natori
et al., 1977, Cancer Res., 37, 3406). X-irradiated
Meth A cells were shown to retain their immuno-
genicity eveni after glutaraldehyde treatment
(0-001% to 0-1% for 30 min) mild heat treat-
ment (45°C for 30 inin) and 1mM iodoacetamide,
each of these procedures being effective in
abolishing the immunogenicity of rat hepatoma
cells. These findings exemplify the powerful im-
munogenicity ofthe murine sarcoma in compari-
son to the rat tumours studied, and reflect the
relative ease with which immunogenic prepara-
tions of acellular tumour antigens may be isola-
ted from the Meth A sarcoma.
HOST CELLS INFILTRATING TU-
MOURS IN VIVO AND IN VITRO REAC-
TIVITY. G. R. FLANNERY, R. A. ROBINs and
R. W. BALDWIN, Cancer Research Campaign
Laboratories, University of Nottingham.
Host lymphoid cells infiltrating a transplanted
methylcholanthrene-induced rat sarcoma (Mc7)
have been separated and tested for anti-tumour
reactivity in vivo and in vitro. Cells derived from
tumouirs growing progressively or from tumours
regressing after BCG contact therapy were
equally effective in the control of Mfc7 in vivo
whenl tested in Wiun assays at effector: target
cell ratios as low as 1-5:1. Cells derived from
progressor tumours, when tested in vitro in
6h and 18h 51Cr-release and 60h 75Se-
methionine-uptake inicrocytotoxicity assays,
reacted with a range of other tumours, although
the specificity of the reactivity varied with the
different tests. Normal rat spleen cells, in-
effective in the Winn assay, were also less effec-
tive than tumour-derived lymphocytes in the
long-term cytotoxicity test, buit showed sig-
nificantly more reactivity in the short-term test,
suggesting that the selenoinethionine assay may
be of greater valhe in predicting antitumour
response in vivo.
NATURAL IMMUNITY TO SOLID TU-
MOURS IN THE RAT IS MAINTAINED
THROUGHOUT REPRODUCTIVE LIFE.
G. R. FLANNERY and C. G. BRooKs, Cancer
Research Canmpaign Laboratories, University of
iVottinghant.
The spontaneous cytotoxicity of normal rat
spleen cells towards a synigeneic methyleholan-
threne-induced sarcoma (measured in a 6 h
Cr-release assay) increased sharply in rats
between 2 and 5 wks of age, but thereafter was
maintained at a constant level until at least 20
months. Cell-mixing experiments indicated that
the very low cytotoxicity in 2-wk-old animals
was due to an absence of cytotoxic cells rather
than the presence ofsuppressor cells. Removal of
macrophages by carbonyl-Fe treatment caused
no change in cytotoxicity levels at any age,
indicating that only NK cell activity was being
detected in this assay, and that cytotoxic or
suppressor macrophages played no role. The
persistence of NK-cell activity against sarcoma
cells throughout reproductive life contrasts with
the reported early decline of NK-cell activity
against leukaemia target cells (Kiessling et al.,
1975, Eur. J. Immunol., 5, 117; Herberman et al.,
1975, Int. J. Cancer, 16, 216; Nunn et al., 1976,
J. Natl Cancer Inst., 56, 393.
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SPONTANEOUS CYTOTOXIC ACTIVITY
IN CELL SUSPENSIONS PREPARED
FROM CONTROL AND HODGKIN'S DIS-
EASE (HD) SPLEENS. S. SERDENGEy:TI,
D. B. JONES, S. V. DIXON anI(d D. H. WRIGHT,
UTniversity Departmnent of I'athology, (eiieral
Hospital, Southanpton.
The paper reports the prelimninary restults of
a study of spontaneous lyinphocyte-mediated
cytotoxicity (SLMIC) against the huimanrmnyeloid
target, line K562. In ouir system the mainl SLMIC
for nlorral bl10ocl is 6t50 + 18 specific cytotoxicity
at an-I effector: target Iratio of 20:1. WN'heii coI-
pared at the same ratio conitrol spleen tissue
obtained incidental to abdominal sturgeiry gav-e a
rnean of 19-1,5%± 1-2 with au llpper' range of
21-3%. In 3 cases of HD the specific 51Cr-
release valuies observed wN-ere 49.90° 37.8% a0 d
46-3%, suiggestirng that there is an increase inl the
SLMC-mediatilng poptulation in the spleetn in H)D.
Depletion of plastic adheIent cells only slightly
reduticed the level of cytotoxicity an-d, where
tested, the "B-enriched" cell poptulationt ob-
tained by depletion- of sheep-rosettinig cells gave
cytotoxicity equal to that of whole lymphocytes.
The "T-enriched" cell fractioin from both HD
and control spleenis gave only lowN 51Cr release,
wi'th a mean of 10%. These data add to those
already ptublished froin this laboratory (Jones
et al., 1977, Biomtled. Express, 27, 177) indicatinlg
fuinictionial disturibanices in the spleetn in HD.
The relationship of an increase in. a cell popula-
tiomi known to kill neoplastic targets preferen-
tially (Jondal et al., 1978, Nature, 272, 62) to the
development of the malignant, process in HI) is
unclear.
THE USE OF CELL FUSION TO
INVESTIGATE THE ANTITUMOUR
EFFECTS OF INTERFERON IN HUMAN
NON-HODGKIN LYMPHOMA. K. SIKORA,
R. LEvY an1d T. MIERIGAN, Dlivision of Oncology
aml Infectiouis lDisease, ,S8tanford Ut1niversity
M1edical Center, Stanford, California, (U.S.A.
Hu4InaIn leucocyte interferon was administeied
to 10 patients wtith lyinphoid neoplasms. 5F
patients wN-ith stage IV nodular lymuphocytic
poorly differenttiated lymuphomna demonstrated
significanit reductions ini the size of' previously
stable or progressiv'e abdominal anid sub-
cutaneouss tuinour inasses. 4 ofthese patients had
received nlo previous therapy. A similar course
of interferon failed to influienice the grow-th of
advancing diffiuse histiocytic lymnphoina in 3
patients who had extensive prior radiotherapy
and chemotherapy. 2 patients wN-ith chronic
lymphocytic leukeimia, are current,l receixving
treatmnent.
The possible nechanlismns by \%hich inter'feroin
could be exerting its tumour-reduicitng effect
were inx-estigated. Detailed ilninunological
monitoring of NLDP patients -evealed an in-
crease in the activity of circuilatiig NK cells
follovued by increased respotnses of peripheral-
blood lymphocytes to several Initogens anid anti-
gens. Atteinpts to obtaini stable tulnour linles
in vitro froin these pattients failed. Howe-er, a
set of huiinan mouse hybrid lines was construc-
ted by ftusing one patient's lymphoma cells with
a inotise myeloma line. Sei-eral of the ftusion
products secreted htumain iinmiunoglobtllin of a
single type. The effects of interferoni oni the
kinetics of cell growth aind immuinoglobulin
secretioni were studied in vitro tIsinlg these cells.
Interferon is species-specific anid as expected it
has nco effect on the mouse myelomna liine. Growth
retardation was nioted in some of the hybrids
aind an attempt was made to map this effect to
a specific chiomosoine.
SERUM PROTEIN CHANGES INBREAST
CANCER. J. 'W. HILLYARD, J. W. KEYSER,
R. ('4. NEWCOMBE and D. J. T. WEBSTER,
(Tni?ersity Departmiients of Surgery, Mlledical
Biochemnistry and Medical Statistics, 1'elsh
National School of Illedicine, Car-diff.
Cimmrent, miietho(ds of staging hi-east cancer are
inseensitive, and uinfortuinately no specific tumouii
inarkerIhas beeni detected in this disease. How-
eve-, nonispecific protein changes are known to
occurI' and the data fromn a small preliminar-y
series suggest that some are related to stage
(Coombes, et al., 1977, Lancet, i, 132).
WVe hav-e studied prospectively 168 patients
suispected of having breast cancer: 39 were
foutnd to have benign bi-east disease and 129
breast cancer ofthe followring Manchester stages:
I: 42, II: 28, III: 44, IV: 15. 14 seruImn proteins
w,vere measured before treatment: albuimin,
o 1 antitrypsin, prealbumnin, a2 nacr-oglobulin,
xI acid glycoprotein, caeruloplasmnin, immnuno-
globullins G, A and M, transferrin, ferritin, C-
reactive protein, pregnancy-associated inacro-
globulirn and /2 iniCm-oglobulin.
There weere statistically significant differences
in both of the comparisons, benign: manligniant,
and Stage I: IN' in the case of 3 proteins (al
acid glycoprotein, C-reactive proteimn anid /2
mnicroglobl]lin).
3 of the other proteins (ferritin, al amiti-
trypsin anid prealbumnin) showTed significant
differences betw!een Stage I anid IVT, but not
betw-een benigrn and malignant.
There was so much overlap between stages
foI all 6 of these proteins that none of themn
w-ould aid initial Inanagement if uised indixi-
dluallv.
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ADJUVANT CHEMOTHERAPY IN
EARLY BREAST CANCER. D. C. SMITH,
D. J. Ross, A. R. RUSSELL and C. S. McARDLE,
Departments of Surgery and Radiotherapy, Vic-
toria Inftrmary, Glasgow.
Although adjuvantchemotherapysignificantly
improves disease-free survival after radical
surgery for primary breast cancer when the
axillary nodes are involved (Bonnadonna et al.,
1976, N. Engl. J. Med., 294, 405), its value after
less radical surgery is not known. In this study,
initiated in 1976, patients with early breast
cancer were treated by simple mastectomy and
axillary clearance. If the axillary nodes were
involved, patients were randomized to receive
postoperative radiotherapy, chemotherapy
(CMF) or radiotherapy followed by chemo-
therapy. 58 patients have now been followed up
for between 1 and 24 years.
Of 24 women receiving radiotherapy alone, 5
died of breast cancer within 2 years and 3 others
had developed widespread metastases (Table).
In contrast, 2/18 patients receiving chemo-
therapy alone had died, and only 2/16 patients
receiving both modalities oftreatment had died.
These early results suggest that, after simple
mastectomy and axillary clearance, adjuvant
chemotherapy improves survival inpatients with
early breast cancer.
Treatment
Radiotherapy (24)
Radiotherapy +
Chemotherapy (16)
Chemotherapy (18)
Recurren
Local Disser
1
1
1
PSYCHIATRIC MORBIDI'
CHEMOTHERAPY AND
THERAPY FOR BREAST CS
COOPER, A. V. M. HUGHSON, C
A. R. RUSSELL and D. C. SM
Psychiatry and Surgery, Victoto
Glasgow.
Adjuvant chemotherapy fol
ectomy may prolong disease-fre
there is little information on its c
Breast Group, 1976, Br. Med
Following simple mastectomy, p:
bidity was studied during a tri
chemotherapy, patients being i
cated to chemotherapy (C), rad
chemotherapy (RT&C) or radic
Two self-rating scales of morbid
the General Health Questior
(Goldberg, 1972; OUP) prov
specific measure; and the Leeds,
of Depression (LSM) and Anxiet
(Snaith et al., 1976, Br. J. Psych
Two groups of survivors were compared: Group
I (C and RT&C) and Group II (RT).
Mean scores on the LSD (Table) show that
depression is significantly greater in Group I
than in Group II at both 12 and 18 months after
mastectomy. On the GHQ, psychiatric mor-
bidity was significantly greater at 12 months,
and on the LSA anxiety was significantly
greater at 18 months. Results indicate that
psychiatric illness, particularly depression, is
greater in patients completing a one-year course
of chemotherapy than in those who had radio-
therapy one year before: and that differences
between the groups are still evident 6 months
later.
TABLE. Mean scores on LSD at 12 and 18 months
after mastectomy
Group I Group II
After Mean Mean
mastectomy + s.e. No. + s.e. No. P
12 months 4-8+0-8 29 1-9+0-6 16 <0-01
18 months 3-6+0-9 20 1-2+0-3 12 <0-02
THE MANAGEMENT OF MALIGNANT
EFFUSIONS WITH BLEOMYCIN. J. M.
TROTTER, J. F. B. STUART, F. McBETH, J. G.
MCVIE and K. C. CALMAN, Department ofClinical
Oncology, University of Glasgow.
lce Intracavitary bleomycin was used in a total of
23 patients with malignant effusions, with an
minated Dead overall complete and partial response rate of
3 5 73% in 22 evaluable patients. 78% of intra-
pleural and 69% of intraperitoneal instillations
- 2 of bleomycin produced significant objective and
2 subjective responses. There were 2 possible drug-
related deaths with this therapy, which was
otherwise well tolerated with low toxicity. Lower
TY AFTER average doses than those previously described
RADIO- (Paladine et al., 1976, Cancer, 38, 1903) have
kNCER. A. F. proved as effective in controlling effusions. In
. S. McARDLE addition, control ofpleural effusionswas accomp- 1ITH, Depts. oflished without the need for under-water sealed
nrta Infirmary drainage. Evaluation of the response ofdifferent
malignancies was statistically not possible,
owing to small numbers. High serum levels of
Ilowing mast- bleomycin in one of the treatment-related
e survival, but deaths suggests that intracavitary doses of
quality (British bleomycin in excess of 40 mg/M2 should be
J., ii, 861). avoided in the elderly.
sychiatric mor-
al of adjuvant A PROSPECTIVE STUDY OF ANTI-
randomly allo- EMETIC DRUGS IN THE MANAGE-
liotherapy plus MENT OF NAUSEA AND VOMITING therapy (RT). ASSOCIATED WITH CYTOTOXIC
lity were used: THERAPY. C. MORRAN, D. A. ANDERSON,
nnaire (GHQ) D. C. SMITH and C. S. McARDLE, Department of
iding a non- Surgery, Victoria Inftrmary, Glasgow. n.1 fl --T n t.i
oy (LSA) Scales
kiat., 128, 156).
Toxic side-effects, particularly nausea and
vomiting, limit the usefulness of some cytotoxic
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reginmens. The value of anti-emetic drugs in
controlling these symptoms is unproved. In a
prospective randomized study of anti-emetic
drugs, active agents were compared with placebo
in women receiving adjuvant chemotherapy
(cyclophosphamide, methotrexate and 5-fluoura-
cil) for breast cancer.
83% of those receiving placebo developed
nausea and 78% vomited, the peak incidence
being between 12 and 36 h after injection.
Severe nausea and vomiting occurred in 65%
and 52% of assessments respectively. Meto-
clopramide, cyclizine and fluphenazine failed
to alter the incidence or severity of gastro-
intestinal upset. The combination of fluphena-
zine and nortriptyline significantly reduced the
severity and duration of nausea and vomiting
(Table). These data suggest that the combination
of a phenothiazine and a tricyclic antidepressant
may be effective in controlling nausea and vomit-
ing associated with this form of chemotherapy.
Affected with:
Nausea
Severe nausea
Vomiting
Severe vomiting
Days free of nausea
Days free ofvomiting
Placebo
(%)
83
65
78
52
41
74
Fluphena-
zine/
Nortrip-
tyline
(°h)
53
21
47
1 1
74
90
p
NS
<0-01
NS
<0-01
< 0 0005
< 0 005
CYCLOPHOSPHAMIDE-INDUCED CYS-
TITIS: ITS CAUSE AND POSSIBLE
CLINICAL SIGNIFICANCE. P. J. Cox and
G. ABEL, Department of Biochemical Pharma-
cology, Chester Beatty Research Institute, London
SW3.
Cyclophosphamide {2-[bis(2-chloroethyl)-ami-
no]tetrahydro - 2H- 1, 3, 2 - oxaza - phosphorine
2-oxide} is widely used as an anti-tumour drug
and as an immunosuppressive agent in non-
neoplastic conditions. This compound and its
isomer ifosfamide are the only clinically used
alkylating agents which cause specific urological
damage, namely interstitial haemorrhagic cys-
titis. This phenomenon was studied in the rat,
using an acute technique (Levy & Harris, 1977,
Biochem. Pharmacol., 26, 1015), and optimum
conditions for protection from toxicity by N-
acetyl-L-cysteine were found. Various metabo-
lites and analogues of cyclophosphamide were
tested, including phosphoramide mustard, nor-
nitrogen mustard, 5,5-dimethylcyclophospha-
mide, diethylamine, diethyl-cyclophosphamide
[2(diethylamino)tetrahydro-2H-1 ,3,2-oxazophos-
phorine 2-oxide], acrolein and 3-hydroxypropyl-
mercapturic acid. Only those capable ofreleasing
acrolein in the bladder caused oedema and
21
haemorrhage (Cox, 1979, Biochem. Pharmacol.,
in press). Protection from toxicity with N-
acetyl-L-cysteine was possible in all cases.
An apparently high proportion of tumours
secondary to cyclophosphamide treatment is
found in the bladder (Puri & Campbell, 1977,
Lancet, i, 1306). This may be the consequence
of 2 occurrences: the presence in patients'
urine of strongly alkylating metabolites of
cyclophosphamide, and the rapid hyperplastic
response ofthe bladder epithelium to damage by
acrolein. Thus patients who may have sub-
clinical cystitis may be at as much risk of drug-
induiced malignant changes as patients suffering
severe bladder toxicity.
TESTOSTERONE METABOLISM BY
HOMOGENATES AND CULTURED
EXPLANTS OF HUMAN BREAST CAN-
CER.W.R. MILLER,F.W.BRANNAN andA. P.M.
FORREST, Department of Clinical Surgery, Royal
Infirmary, Edinburgh.
Homogenates ofhuman breast cancer metabo-
lize testosterone to A4 androstenedione, 5cc
reduced metabolites and oestrogen (Miller &
Forrest, 1976, Br. J. Cancer, 33, 116; Li et al.,
1976, Steroids, 28, 561). However, less is known
about the ability of explants of human breast
cancers maintained in culture to metabolize
steroid hormones. The transformation of 3H-
testosterone by homogenates of 11 human
breast cancers has been compared with
that by explants of the same tumours in
organ culture. Both homogenates and cultures
of all tumours metabolize testosterone to A4
androstenedione, 5cc dihydrotestosterone, 50a
androstanedione and 5cc androstanediols (3cc
17/3 and 3/3 17/3). However, whereas oestradiol
synthesis was detected in 4 homogenates, evi-
dence for oestrogen production was obtained in
only one set of cultures. Metabolism was quanti-
tatively similar in both homogenates and cul-
tures, except for the production of A4 andro-
stanedione, which was greater in cultured sys-
tems. Tumours from 3 patients showed higher
50x reductase activity than the remaining tu-
mours, which was evident both in homogenate
and cultured systems. In 7 cultures metabolites
were characterized separately in explants and
cultture meditum. The percentage production of
metabolites was always higher in explants com-
pared media, whereas the proportion of testos-
terone unmetabolized wascorrespondingly lower.
In summary it has been demonstrated that both
homogenates and explants of human breast
cancer maintained in culture have similar poten-
tial to convert testosterone to other Cl9 steroids,
but perhaps not to oestrogen.
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THE EFFECT OF PROLACTIN AND
OTHER HORMONES ON LACTALBU-
MIN PRODUCTION BY NORMAL AND
NEOPLASTIC HUMAN BREAST TISSUE.
G. D. WILSON, K. L. WOODS* and A. HOWELL,
Departments of Medicine and *Clinical Pharma-
cology, University of Birmingham.
We have previously demonstrated that about
40% of human breast tumours contain measur-
able amounts oflactalbumin (Woods et al., 1977,
Lancet, ii, 14). In order to investigate its utility
as a tumour marker, a better understanding of
lactalbumin physiology in normal and neo-
plastic tissue is required.
Human breast tissue was maintained in organ
culture, in serum-free media, for up to 10 days.
Viability was assessed by light microscopy, and
lactalbumin in the surrounding medium was
assayed by radioimmunoassay (Woods & Heath,
1977, Clin. Chim. Acta, 78, 129). Hormones were
added to medium in the following concentra-
tions, 2-50 ,ug/ml ovine prolactin, 10 jig/ml
bovine insulin, 1 ng/ml cestradiol, 1 ,ug/ml
progesterone, 1 ,ug/ml hydrocortisone.
Of 8 premenopausal normal breast samples
tested, 5 have produced lactalbumin in culture.
All 5 responded to prolactin treatment over 4
days, one of them producing lactalbumin when
there was none detectable initially. One biopsy
sample of pregnant breast tested also responded
to prolactin treatment, producing 200 x more
lactalbumin in culture than normal breast.
2/4 postmenopausal breast biopsy samples pro-
duced lactalbumin and one increased synthesis
and release of lactalbumin after prolonged
exposure to prolactin. One fibroadenoma has
been tested which responded to prolactin. Of 9
scirrhous carcinomas, 5 produced lactalbumin
and none responded to prolactin. A dose-related
response to prolactin was found with normal
premenopausal breasttissue but not with tumour
tissue from the same patient.
Of other hormones tested only insulin and the
combination of insulin, prolactin and oestrogen
have had an effect on normal tissue. No hormone
or combination of hormones has stimulated
lactalbumin production in malignant tissue.
In summary, lactalbumin production can be
stimulated in normal, but not in malignant
breast tissue. Malignant tissue may have defec-
tive prolactin receptors or none.
THE POSSIBLE RELATIONSHIP
BETWEEN SEX CHROMATIN AND
OESTRADIOL RECEPTORS IN HUMAN
BREAST CANCER. N. P. BISHUN, M.
SMETHURST and D. C. WILLIAMS, Research
Department, The Marie Curie Memoriial Foun-
dation, Oxted, Surrey.
Sex chromatin (Barr body) frequency and
cytoplasmic oestradiol receptors have been
determined in 46 human breast tumours. The
division into sex chromatin (SC) positive and
negative groups was made at frequencies of
11%, 16% and 21%. The proportion of tumours
with oestradiol receptors in the SC positive
and negative groups varied with the percentage
frequency taken for this division. At the 11%
level there were too few tumouirs in the SC
negative group to form any definite conclusions,
but when making the division at 16% we found
that the tumours with the higher frequency of
SC were more likely to have oestradiol receptors.
At the 21% level we found that SC frequency
was independent of oestradiol receptors.
ELASTOSIS AND ENDOCRINE STATUS
IN HUMAN BREAST CANCER. J. R. W.
MASTERS*, R. R. MILLISt, R. J. B. King: and
R. D. Rubens§, *Institute of Urology, St Paul's
Hospital, London WC2, t§Imperial Cancer
Research Fund, Breast Cancer Unit, Guy's
Hospital, London SE1, and $Imperial Cancer
Research Fund, Lincoln's Inn Fields. London
TVC2.
Subjective histological assessments in primary
human breast tumours have shown that elastosis
is related to prognosis (Shivas & Douglas, 1972,
J. R. Coll. Surg. (Edin.), 17, 315), oestrogen-
receptor status (Masters et al., 1976, Br. J.
Cancer, 33, 342) and menstrual status (Masters
et al., 1978, Eur. J. Cancer, 14, 303). Further
studies have shown a relationship between
elastosis in the primary tumour and the response
to endocrine therapy (measured objectively
using UICC criteria) of advanced breast cancer,
as shown in the Table. While only 6/51 tumours
contained extensive elastosis, 3 of these patients
obtained a complete response (P < 0.005). In
addition, a combination of elastosis and oestro-
gen receptor status provided a better predictive
index than either feature alone. In conclusion,
elastosis assessment is simple, requires neither
additional tissue nor expertise, can readily be
included in routine pathology reports or meas-
ured retrospectively, and may be ofvaltue in the
management of breast cancer.
Elastosis cateaory
0 1 2
Response to (No (Elastosis (Gross
therapy elastosis) present) elastosis)
Complete 0 3 3
Partial 2 5 0
No change 3 5 1
Progressive dlisease 9 18 2
Total 14 31 6
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OESTROGEN RECEPTORS: A GUIDE
TO PROGNOSIS IN EARLY BREAST
CANCER. T. COOKE, P. MAYNARD, D. GEORGE,
K. GRIFFITHS and R. SHIELDS, Department
of Surgery, University of Liverpool, and Tenovus
Institute for Cancer Research, Cardiff. (Intro-
duced by M. Moore.)
The aim of this study was to define the role
of oestrogen receptor (ER) analysis in primary
breast cancer.
ER was measured by the dextran-coated
charcoal technique in 286 women undergoing
mastectomy for early breast cancer. These
patients have been followed up for 3-39 (mean
19) months.
Data were analysed by life tables and the log
rank test.
64 women have developed proven recurrent
disease.
Patients with ER+ tumours had significantly
fewer recurrences (P < 0 001) than those who
were ER-.
On further analysis there emerged an interest-
ing relationship between ER and the histology
of the lymph nodes. In lymphnode-negative
patients there was a significantly higher rate of
recurrence (P < 0-01) for ER- tumours than
for ER+ ones. In these patients (LN- ER-) the
rate ofrecurrence was the same as in all patients
with involved nodes.
Patients with involved nodes and ER-
tumours had the highest rate of recurrence,
significantly above that of all other groups.
We conclude that ER is a prognostic guide in
early breast cancer and that it is independent of
lymphnode status. We have defined a subgroup
of patients (LN- ER-) who, despite the absence
of axillary-node spread, stand the same high
risk of early recurrence as patients with nodal
involvement.
THE PROGNOSTIC SIGNIFICANCE OF
NUCLEAR OESTROGEN RECEPTORS
IN BIOPSY SPECIMENS OF PRIMARY
BREAST CANCERS. D. C. SMITH, D. CRAW-
FORD, L. LAING and R. E. LEAKE, Division of
Surgery, Victoria Infirmary, and University
Department of Biochemistry, Glasgow.
The presence of cytoplasmic oestrogen recep-
tor (ER) in biopsy specimens of metastatic
breast cancer is now known to improve the
accuracy of prediction of response to hormonal
manipulation. Knight et al. (Cancer Res., 1977,
37, 4669) have reported that the absence of
cytoplasmic ER in primary breast cancers is
associated with early recurrence, independent
ofother known prognostic factors. In this study,
ER was assayed in both the cytoplasmic (C) and
nuclear (N) fractions of biopsy samples of pri-
mary breast cancers. The results in 109 patients
were correlated with survival. 4 groups were
defined according to the presence or absence of
receptor in both cellular fractions C+/N+ (26),
C-/N- (59), C-/N+ (6) and C+/N- (18). Follow
up ranged from 13 to 28 months. Disease-free
survival was highest in the C+/N+ group
(77%), and poorest in the C+IN- group (50%).
Of the 77 patients with no detectable nuclear
receptor, 26% had died of their disease, com-
pared to only 90o of those whose biopsy speci-
mens contained nuclear receptor. These results
suggest that the measurement of nuclear ER
adds to the prognostic information achieved by
measuring cytoplasmic ER alone.
SIMULTANEOUS ESTIMATION OF
CYTOPLASMIC OESTROGEN AND
PROGESTERONE AND NUCLEAR
OESTROGEN RECEPTORS IN HUMAN
BREAST TUMOURS AND CORRELA-
TION WITH CLINICAL RESPONSE. L. G.
SKINNER, D. M. BARNES and G. G. RIBEIRO,
Christie Hospital and Holt Radium Institute,
Manch.ester.
Of 336 primary and 148 metastatic human
breast tumours examined, 58% and 43%
respectively were found to have positive cyto-
plasmic oestradiol-receptor (ER,) activity. 59%
of primary and 56% of metastatic tumours with
ERc activity were also found to possess cyto-
plasmic progestin-receptor (PRc) sites. 13%
of ER- tumours were PR+.
Of 74 patients with advanced metastatic
breast cancer, 57% of those with RE+ tumours
had a clinical response (complete or partial)
to endocrine therapy. Where the tumour was
assayed for both ERC and RPc activity before
hormone therapy was started, 9/12 (75%) of
patients whose tumour contained both ERc
and PRc sites responded, whereas only 3/30
(10%) of patients with negative ER, and PRC
had a clinical response, an indication that
tumours containing both receptors are most
likely to show a high response rate to endocrine
therapy.
Nuclear oestrogen receptor (ER.) assay,
carried out on pellets from tumour-tissue
homogenates, has recently been studied in an
attempt to improve further the prognostic
value ofreceptor measurements. Of 284 tumours
assayed, 77 were positive for all 3 receptors,
130 lacking in any receptor activity. Of the
limited number of patients who have become
eligible for assessment to date, 5/6 with tumours
positive for all 3 receptors have shown a clinical
response, whereas 0/9 patients with negative
status have responded.
Patients with ER+ and PR+ primary tu-
mours tended to have a longer disease-free
interval than patients with PR- tumours,
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irrespective of whether these were ER-+ or
ERC .
PHYSICAL PROPERTIES OF OESTRO-
GEN RECEPTORS FROM BREAST CAN-
CER BIOPSY SPECIMENS IN RELATION
TO CLINICAL PREDICTIONS. L. LAING
and R. LEAKE, Department of Biochemistry,
University of Glasgow.
Oestrogen-receptor status has, in recent years,
become a useful guide to potential response to
hormone-based therapy for breast cancer. It
may also serve as a good prognostic index. We
have previously shown that detection of nuclear
oestrogen receptors in breast-cancer biopsy
specimens may give additional, valuable clinical
information (Laing et al., 1977, Lancet. ii, 168).
An understanding of the full significance of
these nuclear receptors depends on a knowledge
ofboth their exact cellular localization and their
functional integrity. Potential abnormalities in
the translocation to the nucleus of oestrogen
receptor have been investigated in certain breast
tumours. The off-rate of steroid (the rate at
which steroid dissociates from its receptor) has
been measured at various temperatures for
hormone-receptor complex from both cyto-
plasmic and nuclear fractions. It was found to
be significant even at 0°C. The distribution of
hormone-receptor complex between the various
subcellular fractions has been determined and is
considered in relation to potential response to
hormone therapy. The value, in terms ofstabiliz-
ing steroid receptor, of different protease
inhibitors (Trasylol and PMSF), both indepen-
dently and in combination, has been determined
in relation to development ofa routin-e procedure
for receptor assay. An assay procedure based on
our conclusions from the above observations
will be presented in detail.
OESTROGEN RECEPTORS AND RES-
PONSE TO TAMOXIFEN IN SOME
TUMOURS OTHER THAN BREAST. F. R.
MACBETH, K. C. CALMAN, L. LAING and R. E.
LEAKE, Departments of Oncology and Bio-
chemistry, Glasgow University.
There have been anecdotal reports ofresponse
of tumours other than breast to the anti-
oestrogen tamoxifen. We are investigating this
further on a clinical basis, and also by assaying
cytoplasmic and nuclear fractions of tumour
biopsy specimens for oestrogen receptor. If
oestrogen receptor is present, and there have
been reports of it being detected in malignant
melanoma, and a number of normal tissues
including kidney, this would provide a scientific
basis for hormonal therapy in such tumours.
No significant cytoplasmic or nuclear oestro-
gen receptor has been found in 5 biopsy speci-
mens of malignant melanoma, 2 of carcinoma of
stomach, 2 of renal cell carcinoma, nor in the
adjacent normal kidney tissue from one speci-
men. 44 samples of rectal and colonic carcinoma
have been assayed. Cytoplasmic receptor was
detected in 2 and both nuclear and cytoplasmnic
receptor in a third sample.
A number of patients wvith advanced disease,
who were failing on conventional therapy, have
been treated with tamoxifen. There have been
no responses in 6 patients with malignant
melanoma, 3 with carcinoma of colon, 1 with
carcinoma of oesophagus and 1 with adeno-
carcinoma of stomach. There is therefore at
present no clinical evidence nor scientific basis
for treating these tumours with anti-oestrogen
therapy, although the study is continuing.
HORMONE RECEPTORS IN MALIG-
NANT MELANOMA. P. RUMKE, C. B. KOR-
STEN and J. P. PERSIJN, Department of Internal
MUedicine and Department of Clinical Chemistry,
Division of Endocrinology, The Netherlands
Cancer Institute, Amsterdam.
The aim ofthe study is the detection ofoestro-
gen and/or androgen receptors in the cytosol of
metastases of malignant melanoma, in the hope
that successful hormonal therapy in advanced
disease may be related to their presence.
Oestradiol (E2) and dihydrotestosterone (DHT)
receptors were assayed in 43 histologically
proven skin and lymphnode metastases from 34
(17c and 17$) melanoma patients. Only in 2
(female) patients did the metastases contain
more than 10 fmol E2 receptor/mg cytosol
protein, which according to standards used in
breast cancer could indicate a hormonal
dependency. In 4 other patients (3& and l2)
DHT receptor levels were more than 10 fmol/mg
cytosol protein. In 2 young male patients with
advanced disease with DHT levels of 13 and
16, 7 fmol/mg cytosol, hormonal treatment was
unsuccessful.
MELPHALAN AND URINARY OESTRO-
GENS. J. MAXWELL ANDERSON*, J. K. GRANT*
and G. GETTINBYt, *Royal Infirmary, Glasgow,
and tUniversity of Strathclyde, Glasgow.
A test of the concept of chemical suppression
of ovarian function by cytotoxic drugs pre-
viously reported (Anderson et al., 1978, Br. J.
Cancer, 37, 477) revealed no supportive evidence
from follicular and luteal-phase measurements
of plasma oestradiol (E2) in 6 premenopausal
women prescribed repeated 5-day courses of
melphalan after mastectomy for cancer. To
circumvent the difficulties of frequent repeated
blood sampling, 3 of these patients were studied
in greater depth. Early-morning urine samples
were collected on alternate days for 6 months.
5-day courses of oral melphalan were taken, to
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cover the expected inidcycle peaks of E2, in
alternate months. No differences in excretion of
total oestrogens (E) between the melphalan
and non-melphalan cycles were observed, failing
to support the concept of ovarian suppression.
Unexpected early peaks of E were consistently
noted in most cycles. 12 normal premenopausal
women were examined similarly and their cycles
showed no evidence of the early oestrogen peaks
seen in the melphalan-treated patients. This
apparent anomaly is being examined further, in
comparison with the urinary oestrogen profiles
of regularly menstruating cancer bearers never
prescribed chemotherapy.
IMPLICATIONS OF GOMPERTZ
GROWTH KINETICS FOR THE CHOICE
OF TREATMENT SCHEDULES IN CAN-
CER THERAPY. T. E. WHELDON and G. F.
BRUNTON, Radiobiology Research Group, Glasgow
Institute of Radiotherapeutics and Oncology,
Belvidere Hospital, Glasgow.
Most experimental tumours grow more rapidly
when small than large but, as regenerating nor-
mal cell populations do likewise, this provides no
basis for treatment scheduling to discriminate
between normal and malignant populations,
at least for the great majority of cytotoxic
agents. This view is contrary to that of Norton
and Simon (1977 Cancer Treat. Reps., 61, 1307),
who have advocated unorthodox scheduling for
cytotoxic agents in general, on the basis of
tumour growth kinetics.
However, there may exist a small minority of
cytotoxic agents whose limiting host toxicity
is cumulative with dose, but largely independent
of the treatment schedule by which it is given.
Examples ofthis mayincludle the limiting cardio-
toxicity of adriamycin and the limiting pul-
monary toxicity of bleomycin.
For these agents in particular, mathematical-
model studies suggest that tumours following
Gompertz growth kinetics, over at least the
upper part of the growth range, may be treated
more effectively by "late-intensity" schedules
than by schedules of more conventional design.
Experimental appraisal of "late-intensity"
scheduling seems warranted for the special case
of those agents whose limiting toxicity is
cumulative with dose.
THE MODE OF ACTION OF "CHIP"
STUDIED BY THE ANALYSIS OF
CHROMOSOME-ABERRATION PRO-
DUCTION. E. BOCIAN*, M. LAVERICK and
A. H. W. NIAS, The Richard Dimbleby Depart-
rnent of Cancer Research, St Thomnas's Hospital
,7Medical School, London SE1.
* Present address: Zaktad Radiobiologii i Och-
rony Zdrowia, Instytut Badan Jadrowych, Dorodna
16, 03-195 Warszawa, Poland.
Platinum complexes forml inter- anid intra-
strand crosslinks in DNA, and in this they
are similar in their action to bifunctional alkylat-
ing agents (Roberts & Pascoe, 1972, Nature,
235, 282). According to the classification of
Bender (1974, Mut. Res., 23, 197) these agents
fall into the 3rd class ofchemicals which produce
lesions of the "delayed type" and which can be
repaired by recombination and post-replication
processes. Cis-dichloro bis(cyclopentylamine)
platinum II (PAD) has been shown to fall into
this 3rd class of chemicals with respect to its
chromosome-aberration production (Szumiel &
Nias, 1976, Chem-Biol. Interact., 14, 217) in
Chinese hamster ovary (CHO) cells. We now
report results in the same cell system with cis-
dichloro-bis (isopropylamine) trans-dihydroxy
platinum IV (CHIP). Only chromatid-type
aberrations were seen but all types were pro-
duced at the 1st mitosis after treatment in G1
and early S phases. This is contrary to the
findings with PAD, where exchanges were only
seen at the 2nd mitosis after treatment. The
majority of aberrations were breaks and gaps
and the frequency of aberrations was dose-
dependent. No aberrations were seen at the 1st
mitosis after treatment of cells in G2. This
confirms the hypothesis that lesions produced
by CHIP can only be seen after DNA synthesis
has taken place on the damaged template.
(Supported by Grant Number CA 20593 from
the U.S. National Cancer Institute.)
ACTINOMYCIN-D PERTURBATION
OF NUCLEIC ACID SYNTHESIS IN
SYNCHRONIZED MOUSE TUMOUR
CELLS IN VITRO. J. V. WATSON and S. H.
CHAMBERS, MRC Clinical Oncology Unit,
The Medical School, Hills Road, Cambridge.
Flow-cytometry systems enable RNA and
DNA to be estimated simultaneously in intact
single cells by measuring the respective red and
green fluorescence emissions after acridine-
orange staining (Watson & Chambers, Cell
Tissue Kinet., 1978, 11, 415). These techniques
have been used to study the alterations in
nucleic acid content of synchronized EMT6/M/
CC cells due to low doses of actimomycin-D
(ACT-D). The concentrations used were 10 and
100 ng/ml as these span the therapeutic range
that can be achieved in man. With continuous
exposure to the lower dose of ACT-D from mid
S-phase, early S and mid G1 it was found that:
(1) the RNA remained constant at the level
attained when exposure began, (2) a progressive
delay in the cycle time occurred with increasing
exposure time, (3) mitosis was not inhibited. At
the higher dose level we found that: (1) the RNA
decreased approximately exponentially from
the level when exposure began, (2) continuous
exposure fromtheendofG1didnotinhibitmitosis
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although the RNA level was decreasing, but the
cycle time was increased. Continuous exposure
fromthe beginning ofthe cycle at bothdoselevels
inhibited mitosis. A number of explanations can
be given for these results, but the possibility that
RNA messenger which is responsible for sub-
sequent mitosis is synthesized during G1 and
not during a late RNA synthesis should be
considered in this cell line.
THE RESISTANCE OF HYPOXIC
MAMMALIAN CELLS TO CHEMO-
THERAPEUTIC AGENTS. E. SMITH, I. J.
STRATFORD and G. E. ADAMS, Physics Division,
Institute of Cancer Research, Belmont, Sutton,
Surrey.
It is now unequivocably proven that hypoxic
cells are one of the limiting factors in the local
control of some tumours by radiotherapy. The
importance ofthesepotentially clonogenic hypoxic
cells has apparently received scant attention in
the treatment of solid tumours with chemo-
therapy. Recently, it was shown that bleomycin
was less toxic towards exponentially growing
cells which had been rendered hypoxic than to
ftilly aerobic cells (Roizin-Towle & Hall,
1978, Br. J. Cancer, 37, 254). We have confirmed
this result, and in addition have shown that
hypoxic cells are more resistant to treatment by
actinomycin D, adriamycin, 5-FU, Ara-C and
vincristine.
In particular, the toxicity of adriamycin
towards hypoxic cells is dependent upon the
length oftime for which the cells were previously
rendered hypoxic at 37°C. Results will also be
presented which show that previously hypoxic
cells do not immediately recover their sensitivity
to adriamycin when they are made aerobic
again.
METHOTREXATE PROTEIN BINDING.
W. H. STEELE, J. F. B. STUART, J. R. LAWRENCE
and K. C. CALMAN, University Department of
Materia MedicaandClinical Oncology, University
ofGlasgow.
Published estimates for the protein-binding
of methotrexate (MTX) range from 60 to 94%o.
We have assessed the protein-binding of MTX
in serum from 8 healthy subjects by continuous
ultrafiltration; drug levels were measured by
radioimmunoassay.
MTX was found to bind predominantly to
serum albumin. Over the range 1-30 ,uM the
binding was linear at 95-1+2-3% (mean +s.d.)
but at concentrations greater than 50 juM
deviation from linear binding was found.
Protein-binding parameters were obtained from
the analysis ofScatchard curves, which indicated
2 distinct groups of binding sites. In the high-
affinity group these were 0-16+0-05 binding
sites (N1) with an intrinsic association constant
of 71-15X 104/M+35-98 (K1), whereas in the
lower affinity group N2=2-01+0-93 and K2=
0-18 x 104/M + 0-15. Protein-binding of a cytoxic
agent could be of critical importance, in that
anomalies therein might greatly affect the dis-
tribution and excretion of the agent. This is
particularly important where protein-binding is
saturable within a concentrationrangecommonly
produced in vivo, as we have demonstrated for
MTX. Further, the presence of neoplastic
disease, response or failure of response, and
nutritional status could affect the binding
parameters, thereby altering the disposition
characteristics of MTX.
PHARMACOKINETICS OF BLEOMYCIN
FOLLOWING I.M., I.V. OR INTRACAVI-
TARY ADMINISTRATION. J. F. B. STUART,
W. AHERNE, L. PRASAD, S. JAMES, J. M. TROT-
TER and J. G. MCVIE. Department of Clinical
Oncology, University of Glasgow and Department
of Biochemistry, University of Surrey.
The major limitation ofbleomycin administra-
tion by the i.v. or i.m. routes is the occurrence
of pulmonary fibrosis. This side effect, usually
irreversible, is increasingly common above a
total cumulative dose of 300-250 mg/M2. Bleo-
mycin has been advocated in high dose for
treatment of malignant pleural and peritoneal
effusions. Alberts (1978) Proc. Am. Ass. Cancer
Res., 305, have suggested that 40% of an intra-
pleural dose is absorbed, thus contributing to
the total dose limitation. A group of5 levels have
been studied in an attempt to reproduce these
data. Bleomycin levels were measured in plasma
samples removed at 11 times after injection of
the drug either i.m., i.v. or i.p. (intrapleural).
Close agreement with Alberts's data has been
obtained, viz:
TAU(C) (h)
AUC (riog min/mi)
i.m i.v. i.p.
4 7 4-3 6-3
864 903 388
Thus exposuire of the systemic circulation to
bleomycin after 30 mg intrapleural injection is
half ofthat after an i.m. or i.v. dose.
EFFECT OF PHENOBARBITONE AND
PHENYTOIN ON THE PHARMACO-
KINETICS AND TOXICITY OF MISON-
IDAZOLE. P. WORKMAN, C. R. WILTSHIRE and
N. M. BLEEHEN, MURC Clinical Oncology Unit,
Hills Road, Cambridge.
Concentrations of the hypoxic cell radio-
sensitizer misonidazole (MIS, Ro 07-0582) and
its 0-demethylated metabolite Ro 05-9963 were
determined in plasma (or blood), tumour and
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brain after an injection of 1 g/kg MIS i.p. to
mice pretreated with phenobarbitone, phenytoin
or saline vehicle. Analysis was HPLC (Workman
et al., 1978, J. Chromatogr. 145, 507).
Phenobarbitone and phenytoin pretreatment
did not alter the peak MIS concentration in
plasma, brain or tumour, but did reduce the
apparent elimination half-life (ti) and area
under the cturve (AUC) for MIS in all 3. The
decrease in tJ from 2 to 1 h was associated
with an increased Ro 05-9963 metabolite con-
centration. The AUC for total 2-nitroimidazole
was also reduced in plasma, tumour and brain
by 20-500.
Both phenobarbitone and phenytoin increased
the acute LD50 for MIS in mice from 1-54 g/kg
to 1-90 g/kg and 1-78 g/kg respectively (P <
0.001).
Preliminary studies in man indicate that
phenytoin reduces the MIS t- by increasing
MIS 0-demethylation.
INHIBITION OF HEPATIC MIXED-
FUNCTION OXYGENASES BY CYTO-
TOXIC AGENTS IN VITRO. A. GESCHER
and A. E. GREEN, Cancer Chemotherapy Group,
Department of Pharmacy, University of Aston,
Birmingham.
Inhibition of depression of drug-metabolizing
enzymes may have severe clinical consequences
in cancer chemotherapy, as many antitumour
drugs exert their cytotoxic activity only after
metabolic activation, predominantly in the liver.
Most of them are also detoxified by the liver. If
repeated treatment with a cytotoxic agent or its
concurrent administration with other drugs as
part of a combination regime implicates adverse
effects on drug-metabolizing enzymes, altered
bioactivation or detoxification patterns may
cause diminished or changed therapeutic res-
ponse to chemotherapy.
We investigated the ability of procarbazine,
lomustine, carmustine, chlorozotocine, hexa-
methylmelamine, dacarbazine and the experi-
mental antitumour triazene p-carbmethoxy-
phenyldimethyltriazene and some of their
metabolites to inhibit the metabolic 0-
demethylation of p-nitroanisol in livers of male
CBA LAC mice in vitro. This reaction is a model
for metabolic functionalization reactions cata-
lysed by mixed-function oxygenases (Netter,
1964, J. Pharmacol. Exp. Ther., 146, 61). Sig-
nificantly, all the drugs studied require oxidative
bioactivation. Dacarbazine and chlorozotocine
showed no inhibition at all at concentrations
<5 mM. All the other agents interfered with
drug-metabolizing enzyme activity. Dixon plots
(Dixon, 1952. Biochem. J., 55, 170) indicated
non-competitive or uncompetitive inhibition
for most agents, with Ki values in the [kM or
mM range. Procarbazine increased inhibition
after 15 min preincubation in buffer before the
addition of liver homogenate, which indicates
that a metabolite of the labile drug molecule
contributes to drug metabolism interactions
with procarbazine.
UNEXPECTED LOSS OFANTI-TUMOUR
ACTIVITY IN A HOMOLOGOUS
SERIES OF 3-ALKYL-1-ARYL-3-
METHYLTRIAZENES. D. E. V. WILMAN,
P. J. COX, P. M. GODDARD and K. MERAI,
Department of Biochemical Pharmacology, Insti-
tute of Cancer Research, London SW3.
The continuing clinical interest in DTIC,
despite its severe side effects, has prompted us
to apply our earlier structure-activity results
(Connors et al., 1976, Biochem. Pharmacol.,
25, 241) to this drug-design problem, in the
search for a second-generation agent. An
extended homologous series of 3-alkyl-l-(4-
carboxyphenyl)-3-methyltriazenes shows un-
expected loss of anti-tumour activity at alkyl
chain lengths greater than 5 carbon atoms.
Physicochemical parameters, in particular solu-
bility at pH 7-4 and octanol-buffer partition
coefficients, show no similar sudden breaks.
It has proved impossible to detect any in
vitro dealkylation of these compounds, and we
therefore turned our attention to the analogous
3 - alkyl - 1 -(4 - carbamoylphenyl) - 3 -methyl -
triazenes, which exhibit a similar pattern of
anti-tumouractivity. In this series aconsiderable
degree of in vitro demethylation and dealkyla-
tion occurs in compounds with anti-tumour
activity, but both are markedly reduced in those
lacking activity.
IN VITRO CYTOTOXICITY OF HEXA-
METHYLMELAMINE AND ITS ANA-
LOGUES. C. J. RUTTY, G. ABEL and K. R.
HARRAP. Dept. of Biochemical Pharmacology,
Institute of Cancer Research, London SW3.
Hexamethylmelamine (HMM) and a number
of its derivatives are toxic to PC6 plasma-
cytoma cells in vitro, and a number of N-
methylrnelamines have also shown significant
activity against this tumour in vivo. N-methylol-
melamines are significantly more toxic in vitro
than HMM itself. These compounds break down
to release formaldehyde, which is itself highly
cytotoxic. Pentamethylmonomethylolmelamine
rapidly inhibits the growth of PC6 cells in
culture, whereas HMM and pentamethyl-
melamine (PMM) require prolonged contact with
the cells in order to exert a cytotoxic effect.
HMM and its metabolites are also toxic to a
number of other cell lines in vitro, although
without effect in vivo. The toxicity of N-
methylols to L1210 and Walker ascites cells
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can be completely reversed using semicarbazide,
whereas their toxicity to PC6 cells is irreversible,
although in all cases the toxicity of formalde-
hyde itself can be reversed. These findings
suggest that, in tumour cells which are sensitive
in vivo, the N-methylols are able to exert a more
selective effect than formaldehyde. ILMM,
PMM and PMM-methylol rapidly inhibit both
DNA and RNA synthesis in vitro. These effects
are rapidly and completely reversible for un-
metabolized PMM after removal ofthe drug, but
totally irreversible for the methylol, suggesting
a different mechanism of action. The methylols
may exert their effects on nucleic acid synthesis
by direct inhibition of DNA template activity.
EFFECT OF CHLORAMBUCIL ON
NUCLEAR PROTEIN PHOSPHATASES.
P. J. THRAVES, R. WILKINSoN and K. R.
HARRAP, Dept. of Biochem. Pharmacol., Institute
of Cancer Research, >Sutton, Surrey.
The alkylating agent chlorambucil increases
nuclear protein phosphorylation in Walker 256
ascites tumour cells sensitive to the toxic action
of alkylating agents, but not in a paired line
resistant to a wide range of alkylating agents.
However, binary combinations of chlorambucil
and the steroid prednisolone also increase
nuclear protein phosphorylation in the resistant
tumour. Fractionation of nuclear protein phos-
phatases and kinases show the phosphatases to
be located in the nucleoplasm and the kinases
in the non-histone chromosomal protein. 10-
week-old female Wistar rats bearing either
sensitive or resistant cells were treated with 10
or 20 mg/kg of chlorambucil. Tumour cells
were collected 48 h later and nuclei prepared
(Rickwood et al., 1973, Biochim. Biophys. Acta,
299, 162.). Phosphatase activity was determined
by the decrease in activity of nuclei previously
labelled by incubation with y32P-ATP. Neither
chlorambucil nor a combination ofchlorambueil
plus prednisolone induces a significant inhibition
of nuclear protein phosphatase activity in
either alkylating-agent-sensitive, or resistant
tumour cells. We cannot therefore explain the
observed increase in total nuclear protein
phosphorylation by a modification of phos-
phatase activity. Studies on the isolation and
characterization of nuclear protein kinases are
in progress to determine their role in the
increased phosphorylation.
FACTORS INFLUENCING THE PRO-
TECTION OF TUMOUR CELLS FROM
5-FLUOROURACIL TOXICITY BY THY-
MIDINE. J. F. R. MUINDI, S. E. BARRIE and
K. R. HARRAP, Dept. of Biochemical Pharma-
cology, Institute of Cancer Research, Sutton,
Surrey.
There has been recent interest in the use of
thymidine (TdR) to modulate the effects of
5-fluorouracil (FU) (Martin et al., 1978 Proc.
Am. Ass. Cancer Res., 19, 251). Based on the
idea that TdR will supply the thymidylate the
de novo synthesis of which is prevented by 5-
fluorodeoxyuridylate, it should be possible to
protect all cell lines from FU toxicity in vitro.
This, however, is not the case (Reeves et al.,
1969, Proc. Soc. Exp. Biol. Med., 131, 1068). A
study of the factors which affect the protection
was undertaken to see whether there could be a
rational basis for the use of FU/TdR combina-
tion in man. Ehrlich ascites tumour cells were
protected from FU toxicity by TdR in tissue
culture, whereas Walker carcinosarcoma 256
were not. Uridine failed to protect either of
these cell lines. The incorporation of FU into
RNA was not affected by TdR, and did not differ
between the 2 cell lines. Studies of the enzyme
responsible for TdR utilization (thymidine
kinase) and degradation (dihydropyrimidine
dehydrogenase DHPD) showed that the degra-
dative pathway alone differed, being 24 pmol/h/
mg protein in Walker careinosarcoma 256 cells
and undetectable in Ehrlich ascites tumour cells
(i.e. < 8 pmol/h/mg protein). It is suggested that
only those tissues with a low activity of DHPD
wNill be protected from FU toxicity by TdR.
2-AMINO-4-HYDROXY QUINAZOLINE
ANALOGUES OF FOLIC ACID AS THY-
MIDYLATE SYNTHETASE INHIBITORS.
T. R. JONES, A. H. CALVERT, A. L. JACKMAN,
S. BROWN and K. R. HARRAP, Dept. of Bio-
chemical Pharmacology, Institute of Cancer
Research, Sutton, Surrey.
Certain quinazolines which mimic the folate
ratherthan thepyrimidine substrate are effective
inhibitors of thymidylate synthetase (TS)
(Paine et al., 1978, Br. J. Cancer, 38, 180).
Desirable features of these compounds are their
independence of metabolic activation, and the
improbability of their incorporation into nucleic
acids which may be the cause of the delayed
toxicity of FU. The substitution of a methyl
group at the 10 position of H-(p(((2-amino-4-
hydroxy-6-quinazolinyl)methyl)amino)benzoyl)-
L-glutamic acid increases its ability to inhibit
bacterial TS 10-fold (Bird et al., 1970, Mol. Phar-
macol., 6, 573). A series of these compounds,
including other 10 substitutions, has been
synthesized and evaluated, viz:
'50 for
I50 for TS (nM) L1210
House 10 ,- A - culture
no. Substitution L1210 L. casci (/iM)
CB 3705 H 570 860 2-2
CB 3713 Me 42 64 4
CB 3714 Et 27 38 16
CB 3715 Pr 260 1100 40
CB 3719 Bu 3200 480
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I'he inhibition of CB 3705 is competitive with
5,10-CH2-THF (Ki= 67 nM, L1210 enzyine).
Assuming that CB 3714 is also competitive, its
Ki w-ill be 3-2 nM, which is comparable to
5FdULATP (Reves & Heidelberger. 1965,
Mol. Pharmacol., 1, 14). All of these compounds
are reversible by thymidine in tissue culture.
These studies may provide a "second generation"
alternative to methotrexate (MTX) which will
circumvent AITX resistance.
PART II
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TUMOUR INCIDENCE IN MICE AFTER
OESTROGEN AND PROGESTERONE
TREATMENT. A. E. LEE, Imtperial Cancer
Research Fund, London ll'C2.
The wxidespread clinical Use of ovarian hor-
inoties has led to renewed interest in the possible
earcinogeniicity of these compounds.
()estromie (40 iig/ml drinking wNater) was given
to 98 ovariectomized C57 BL inice continuously
froin 4-5 inoniths of age uintil death, a mean
period of 215 i months (range 11-31). Half
(Grotip 0 + P) received a total of 13 s.c. injections
of progesterone (1-0 mg in oil) during weeks
1-4 anid 26'39; at the same times the remainder
(CGIo7up 0) received 0-5 nl vehicle.
At autopsy, no inamninary, uterine or cerv-ical
tuimours were foutrd in either grouip. The inost
cominon-. abnormalities wNere lynphoid tumnours
or itnfiltrations. AMost occurred in mice aged 24-
30 months, in the following tissues (Group 0
giv-en first); gut and mesenteries (46°O%, 46%);
spleen (36%, 40%); liver ('15% 21%); kidney
(2o%, 2%o). Also, 4 subcutaneous lymnphosar-
coinas were seeii in Group 0. Haemangioinas were
noticed in the liver (2%, 8%). Two mice in
(Iroup 0, and I in Group 0 + P developed a
spindle-cell sarcoina otn the back (the site of
jijectionl).
WN'hen these restults wNere coinpared with the
data of Row-latt et al. (1976, Lab. Anim. Sci.,
10, 419), who used C57BL mice from the same
breeding colony and kept tunder the same condi-
tionls, therIe were rio significant differences in
tuInouir distribtution. It appears therefore that
lonig-terin adinitiistration ofoestrogen, or oestro-
geni and progesterone, does Inot alter the normal
organ distributioni of carcin-ogenesis in ageing
C57BL inice, nior induice ttumours in taIrget
organs.
THE EFFECT OF LYOPHILIZATION ON
THE ACTIVITY OF OESTRADIOL AND
PROGESTERONE RECEPTORS. E. J.
LLOYD, D. A. BARNES anrd L. G. SKINNER,
Clinical Research Laboratories, Christie Hospital
an2d Holt Radiumi Institute, Mllanchester.
The stor-age arid tiainsport of steroid hormnone
receptor-contairiing tisstue is limited by the
22
instability of the receptor proteins involved.
Lyophilization of the tisstue mnay yield a more
stable product which would prove usefuil for
quality-control investigations between labora-
tories.
The effect of lyophilization on the activity
of the oestradiol (ER,) and progesterone (PR,)
receptors in human breast-tumouir tissue and
normal uterine tissue, has been studied. ER,
and PR, activity in cytosol was determrined by
a dextran-charcoal (DCC) method (Korenman
& Duikes, 1970, J. Clin. Endocrinol. 30, 659)
using 3H-oestradiol and 3H-R5020 respectively.
Oestrogen receptor activity in the "nuclear"
debris (ERn) was determined by the mnethod of
Laing et al., (1977, Lancet, ii, 168). The dis-
sociation constant (KD) and number of receptor
sites were calculated from Scatchard analyses
of the data.
From the results obtained the activity in the
lyophilized tissue was expressed as a percentage
of the activity prior to lyophilization. The mean
values for ER, (17 samples) PR, (5 samples)
andER1n (8 samples) were 94°/I 112%, and 157%
respectively. The dissociation constants did not
differ significantly.
Receptor activity, therefore, survives lyo-
philizationi for both ER, and PR, and lyophil-
ized tissue can subsequently be stored without
loss of activity. This procedure may be advan-
tageous in receptor purification, and at present
lyophilized tissue isbeingusedfor quality control.
GLYCOPROTEIN HORMONE ot SUB-
UNIT AND SURVIVAL IN MELANOMA
PATIENTS. I. A. MIAcFARLANE, N.
THATCHER*, R. SWINDELL, C. G. BEARDWELL,
E. HAYWARD and D. CROWTHER*, Endocrinology
Department and *CRC Department of Medical
Oncology, Christie Hospital and Holt Radium
Institute, MWanch,ester.
The common oc subunit of the glycoprotein
hormones (LH, FSH, TSH and HCG) is raised
in the blood of patients with various malignant
conditions (Dosogne-Guerin et al., 1978; Eur. J.
Cancer, 14, 525). We measured serum a subunit
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levels in 55 patients with melanoma before and
during chemoimmunotherapy. The upper limit
ofnormal in menand premenopausal women was
2-3 ng/ml and in postmenopausal women 9.5
ng/ml.
In 20 premenopausal patients oc levels before
therapy ranged from < 0 5 to 10 ng/ml, median
2-3 ng/ml. 10 had levels above the upper limit
of normal, median 6-8 ng/ml. The median sur-
vival in patients with elevated a levels was 19
weeks, compared to a median survival of 83
weeks in those with normal a levels. This
difference was significant (P= 0-015, Log rank).
In 11 postmenopausal patients a levels before
therapy ranged from 0-5 to 13 ng/ml, median
3-5 ng/ml. Median survival of these 11 patients
was 26 weeks. Only 1 had a raised a level, and
this patient died at 20 weeks. In 24 male patients,
a levels before therapy ranged from <0-5 to
10 ng/ml, median 0 5 ng/ml. The median survival
of these 24 patients was 32 weeks. Only one
had an elevated a level, and this paticnt died at
8 weeks.
During therapy, 1 further premenopausal, 1
postmenopausal and 4 male patients developed
a levels above the upper limit of normal. Maxi-
mum a levels during treatment, levels at docu-
mented regression or progression of disease and
levels at the end oftherapy, did not significantly
influence survival of patient groups.
Conclusions: oc subunit levels are raised in up
to 50% ° of premenopausal patients with mela-
noma before treatment and are associated with
reduced survival. In men and postmenopausal
women oc levels are infrequently raised.
COMPARISON OF PAM AND CEA AS
DETECTORS OF MAMMARY MICRO-
METASTASES. J. MAXWELL ANDERSON*,
S. K. JHUNJHUNWALA*, J. M. EWAN*, W. H.
STIMSONt and G. GETTINBYt, *Royal Infirmary,
Glasgow and tUniversity of Strathclyde, Glasgow.
Nineteen of 61 Stage I or II mammary-cancer
bearers developed conventionally detectable
metastases within 8-44 (median 15) months of
commencing follow-up. Serum pregnancy-asso-
ciated macroglobulin (PAM, PAG, O2 PAG)
rose by > 75% above baseline values before
detection of metastases in all but 4 of these 19
patients and in 11/42 remaining well. The means
of the maximum percentage rises in PAM were
286 for the metastatic and 67 for the well
patients (P<0-01 in a Mann-Whitney U-test).
In contrast there was a similar rise of serum
carcinoembryonic antigen (CEA) in only 6/19
patients with metastases (1 other rose >75%
above the baseline but fell before metastases
appeared) and 13/42 clinically well patients had
rises greater than the 75% level. The predictive
performance of CEA was not bettered by taking
a 45% rise as the discriminant, or by using a
function ofthe combined rises in PAM and CEA,
and the difference between the maximum per-
centage rises in the metastatic (92) and the well
(106) patients was not significant. Thus CEA
changes do not discriminate between those
about to manifest macrometastases and those
remaining well, but PAM rises exceeding 75%
often do this with apparent odds of nearly 2 to
1 on the clinical appearance of these metastases
within a year or so.
MORPHOLOGICAL FEATURES OF
THIRTEEN MURINE MAMMARY
TUMOUR CELL LINES. A. J. COCHRAN,
N. KUZUMAKI, I. A. R. MORE and G. KLEIN,
Pathology Department, WVestern Infirmary, Glas-
gow, and Dept. Tumour Biology, Karolinska
Institute, Stockholm, Sweden.
Seventeen transplantable spontaneous and
virus-induced mammary tumours from various
strains of mice were cultured in an effort to
obtain established cell lines. This was success-
fully achieved with 13 lines, which on regular
subculture grew as monolayers and produced
tumours in syngeneic mice. Histological exam-
ination of such tumours showed that 7 were
adenocarcinomas, 3 were solid carcinomas and
3 had a spindle-cell morphology associated with
abundant pericellular reticulin and collagen.
The light-microscopic appearances of the 3
spindle-celled tumours suggested that they were
sarcomas, but ultrastructural examination
showed features characteristic of epithelial
cells, proving them to be spindle-celled car-
cinomas.
SURFACE FEATURES OF TRANS-
PLANTABLE MOUSE COLON CANCERS.
J.A.DOUBLE*,M.C.BIBBY*andJ. C.KNOWLESt,
*Postgraduate School of Studies in Medical and
Surgical Sciences, University of Bradford, and
tUnit for Cancer Research, School of Medicine,
University of Leeds.
We have previously reported the development
and characterization of an ascitic line from a
solid transplantable mouse adenocarcinoma of
the colon. (Double & Cifuentes de Castro, 1978
Cancer Treat. Rep., 62, 85). Using the methods
described we have produced another ascitic
variant designated MAC 13/A from the solid line
MAC 13. The histology of MAC 13 has been
previously described (Double et al, 1975,
J. Natl Cancer Inst., 54, 27). This study describes
the surface features of the cells in the solid
ascitic lines.
Initially the tumour fragments consist of
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individual cells attached by desmosomes. Free
surfaces of the cells adjacent to lumina bear
microvillus-like processes. Tumour cells adjacent
to the lumen are attached by typical epithelial
junctional complexes comprising zonula occlu-
dens, zonula adherens and desmosomes. The
ascites line consists of either single cells or
clumps. Scanning electron microscopy indicated
irregular folding of the cell surfaces. Trans-
mission electron microscopy revealed that the
clumps of cells consist ofindividual tumour cells
attached by desmosomes and tight junctions.
Microvillus-like structures project from the free
surfaces of the cells into intercellular lumina or
vesicles. The considerable degree of differentia-
tion shown by these clumps of cells would
emphasize the usefulness of these tumour lines
in experimental chemotherapy.
Future studies will examine the ultrastructure
ofsystemic tumours produced by i.v. inoculation
of ascites cells.
ESTABLISHMENT OF LONG-TERM
CELL CULTURES FROM EQUINE SAR-
COIDS. A. DOYLE, L. N. OWEN and T. D.
LITTLEWOOD, Department of Clinical Veterinary
Medicine, University of Cambridge
Equine sarcoids are spontaneous connective-
tissue tumours which can occur at many dif-
ferent sites. Histologically they appear as
fibromas or low-grade fibrosarcomas, and have
a high tendency to recur after excision. They
have some pathological resemblance to the
human dermatofibrosarcoma protuberans. Evi-
dence of cell-free transmission is not totally
convincing, but the tumours may have a viral
origin, and this is being investigated.
In the establishment of tissue cultures the
first technique used for the disaggregation of
biopsy material involved incubating minced
tissue in 0 25% trypsin/Hanks' BSS with anti-
biotics at 37°C for 3-4 and 16-20 h. This led to
the successful culture (i.e. > 20 subcultures) of
2/7 tumour samples; both were derived by
long-term trypsinization. However, this has
been superseded by a more successful technique
in which the minced tumour tissue is incubated
at 37°C in normal growth medium supplemented
with antibiotics, and containing 200 u/ml
collagenase. A well-dispersed cell suspension is
given after incubation for 24-72 h. Thus 16/25
tumours have been established in culture. The
added advantage of this method is that tissue
canbetransported inthedisaggregationmedium,
so enabling a larger number of samples to be
obtained from clinicians in distant parts of the
country. Cultures have been established from
tumour material received up to 6 days after
excision; the only major problem which remains
is gross contamination from the tumours which
often show secondary infection.
The research is supported by the Horserace
Betting Levy Board.
INHIBITION OF MEMBRANE ATP-ASE
ENZYMES BYANTITUMOURALKYLAT-
ING AGENTS. J. A. HICKMAN and G. E.
SPURGIN, Cancer Chemotherapy Group, Depart-
ment ofPharmacy, University of Aston, Birming-
ham, B4.
It has been suggested that alkylation of DNA
may not alone be able to account for the anti-
tumour activity of alkylating agents (Wheeler,
1967, Fed. Proc., 26, 885). We have considered
plasma membrane ATPase enzymes as possible
targets for the alkylating agents which may
explain their cytotoxicity. These enzymes are
implicated in the control of cell proliferation
(Quastel & Kaplan, 1970, Exp. Cell. Res., 62,
407; Sanui & Rubin, 1978, J. Cell Physiol.,
96, 265) have raised activity in transformed
cells (Kasorov & Friedman, 1974, Cancer Res.,
34, 1862) and are inhibited by alkylating agents
(Skou, 1963, Biochem. Biophys. Res. Commun.,
10, 79).
A study has been made of the enzymes from
a plasma-cell tumour (PC6) which is sensitive
to alkylating agents in vivo, and we have charac-
terized Na+K+ ATPase (E.C.3.6.1.3)Mg2+
ATPase, an external Ca2+ ATPase and p-
nitrophenolphosphatase (E.C.3.1.3.1) activities
in a crude cell-membrane preparation from this
tumour. Nitrogen mustard (HN2) inhibits in a
time-dependent manner 90% of Na+K+
ATPase activity at 9 x 10-15M, Mg2+ ATPase
(jDo= 7 x 10-15M) and has little effect on either
external Ca2+ ATPase (IDo > 10-4M) or p-
nitrophenylphosphatase (IDso > 10-4M). A com-
parison of nitrogen mustard with monofunc-
tional alkylating agents (e.g. iodoacetate, N-
ethylmaleimide) showed it to be by many orders
of magnitude more potent as an inhibitor of
Na+K+ATPase.
CYTOTOXIC-NON-CYTOTOXIC DRUG
INTERACTION. J. F. B. STUART*, and I. H.
STOCKLEYt, *Department of Clinical Oncology,
University of Glasgow, and tDepartment of
Pharmaceutical Chemistry, Nottingham Univer-
sity.
As a group, patients on cytotoxic chemother-
apy are at the top of the bad-risk league with
regard to possible drug interactions. The drug-
interaction alert chart (Stockley), Medidisc
(Whiting) and the booklets, Safer Prescribing
(Beeley) and Drug Interaction Guide (Abbot)
are of help to the physician. However these
publications fall short in only providing limited
information relating to cytotoxic-non-cytotoxic
drug interactions. A chart has been prepared to
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illustrate not only the possible cytotoxic-non-
cytotoxic adverse interactions, but also some of
those interactions which occur between cytotoxic
drugs themselves. An additional feature of the
chart is that it highlights the non-cytotoxic-
cytotoxic adverse interactions pertaining to
that group of drugs on the chart. The specialized
nature of oncology and the need to emphasize
the clinical significance of possible adverse
initeractions are met by a simple reference card
system to be used in conjunction with the chart.
CHROMOGENIC SUBSTRATE ASSAY
FOR PLASMINOGEN ACTIVATOR, US-
ING LEWIS LUNG CARCINOMA AND
SV40-3T3 CELLS IN TISSUE CULTURE.
P. WHUR, J. BOSTON, M. MAGUDIA and D. C.
WILLIAMS, Cell Biology Unit, Marie Curie
M1emorial Foundation, The Chart, Oxted, Surrey.
A simple and rapid liquid assay for plasinino-
gen activator (PA) production by cells in tissue
ctultuire has been developed, which is nontoxic
and uses only commercially available products.
Cells in 35 mm Petri dishes were incuibated for
4 h in 0-8 ml serum-free indicator-free medium
(Flow Laboratories) containing plasminogen
(KabiVitrum, 0 5 cu/ml) and the chromogenic
stubstrate S-2251 (KabiVitrum, 385 ,ug/ml).
Activation converts the plasminogen to plas-
min, which degrades S-2251 to release a yellow
dye. Changes in optical density (OD405) were
calibrated against a plasmin (KabiVitrum,
< 0-I cu/ml) standard curve, to measuire the
PA activity of the cells.
The assay was extended to 24 h by adding
10% serum free of plasminogen and inhibitors
of plasmin (Northumbria Biologicals). High
backgrounds were generated by the serum, but
this form ofthe assay allowed longer-term studies
in growth-supporting media.
Changes in OD405 were linear with activator
concentration when urokinase (Leo Labora-
tories, < 5 cu/inl) wvas used. The plasmin stan-
dard curve was also linear, but small amounts
of plasmin were lost on the vessel walls. PA
production was linearly related to cell density
in the 2 cases examined. The preferred numn-
ber of cells ranged from a few thousand to a
million, depending upon their PA activity. Cells
which generated high levels of plasmin rounded
uip slightly owing to proteolysis, btut they were
otherwise tunaffected by the assay and couild be
re-uised.
AN EPIGENETIC MODEL FOR THE
GENESIS OF PARANEOPLASTIC SYN-
DROMES. G. V. SHERBET, Cancer Research
Unit, Royal TVictoria Infirmary, Newcastle upon
Tyne.
Cell differentiation is know-n to involve a
progressive determination and restriction of
competences and a sequential gene activation.
It is proposed that neoplastic changes include a
process of dedetermnination and an acquisition
of a previous state of competence, and that this
leads to an abnormal activation ofgenes.
Paraneoplastic syndromes of endocrine dys-
function can be classified on an epigenetic basis
of the degree of dedetermination which the
neoplasms may have undergone. It is proposed
that Group I neoplasms have acquired the
preceding competence (Group IA, e.g. bronchial
carcinoma syndromne hyperadrenocorticism;
both neoplasm and endocrine syndrome of
bronchial endoderm origin), or one of several
earlier stages of competence (Group IB, e.g.
primary hepatoma syndrome hypercalcaemia,
both endodermal in origin but not as closely
related as in IA). Group II tumours (e.g. renal
carcinoma syndrome erythrocytosis) have to
undergo more extensive dedetermination than
Group I. Group III neoplasms (e.g. adreno-
cortical tumour, mesodermal origin syndrome
hypoglycaemia, endoderm-derived endocrine
function) show a highly labile state of deter-
mination. This epigenetic classification seems to
correlate with the pattern of frequency of inci-
dence of paraneoplastic syndromes (Sherbet,
1974, Ann. N.Y. Acad.Sci., 230, 524).
DEMONSTRATION OF HUMAN AND
MOUSE COMPONENTS OF HETERO-
TRANSPLANTED TUMOURS. H. M.
WARENIUS and N. M. BLEEHEN, MRC Clinical
Oncology Unit, Hills Road, Cambridge.
It has been demonstrated that, with the excep-
tion offoetal tissues (Povlsen et al., 1974, Nature,
248, 247) normal cells will not proliferate when
injected into immunosuppressed mice (Stan-
bridge, et al., 1975, Cancer Res., 35, 2203. It
might thus be expected that human tumours
transplanted to immunosuppressed mice would
acquire a mouse stroma. This possibility has
been investigated using fluorescein-conjuigated
IgG fractionis prepared from the sera of rabbits
immunized with either pooled huinan buffy-coat
cells or mouse thymocytes. Paraformaldehyde-
fixed frozen sections were stained with these
immnunoglobulins and counterstained with pro-
pidium iodide. Antibody specificity was checked
on frozen sections of mouse and human colon
and on a human lung squamous-cell carcinoma.
Application of the technique to a human colonic
adenocarcinoma cell line, 2 squamous-cell
lunrg carcinomas and a mucin-secreting lung
adenocarcinoma groxwrn as xenografts in im-
mnunosuppressed mice showed that, whilst the
main tumour mass stained with anti-humani
serum but not with anti-mouse serum, the
strornal and vascular elements stained distine-
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tively with the aInti-inotuse seruim but Inot the
anti-human serum. Differential counting of
photographs of stained frozen sections revealed
about 750 of the tumour mass to be of human
origin and about 2O5% to be mouse.
323
These studies thus conifirm the chimaeric
nature of human tumours heterotransplanted to
immunosuppressed mice. Results obtained with
this model system may thus need to be inter-
preted in the light of these findings.